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Résumé 
Les maladies cardio-vasculaires (MCV), telles que l’hypertension et l’athérosclérose, 
s’accompagnent de modifications structurales et fonctionnelles au niveau vasculaire. Un 
fonctionnement aberrant de la migration, l’hypertrophie et la prolifération des cellules 
musculaires lisses vasculaires (CMLV) sont des évènements cellulaires à l’origine de ces 
changements. L’endothéline-1 (ET-1) contribue à la pathogénèse des anomalies vasculaires, 
notamment via l’activation des protéines MAPK et PI3-K/PKB, des composantes clés impliquées 
dans les voies prolifératives et de croissance cellulaires. Il a été suggéré que le stress oxydant 
jouerait un rôle intermédiaire dans les effets pathophysiologiques vasculaires de l’ET-1. En 
conséquence, une modulation de la signalisation induite par l’ET-1 peut servir comme éventuelle 
stratégie thérapeutique contre le développement des MCV.  Il apparaît de nos jours un regain 
d’intérêt dans l’utilisation des agents phyto-chimiques pour traiter plusieurs maladies. La 
curcumine, constituant essentiel de l’épice curcuma, est dotée de plusieurs propriétés biologiques 
parmi lesquelles des propriétés anti-oxydantes, anti-prolifératrices et cardio-protectrices. 
Cependant, les mécanismes moléculaires de son effet cardio-protecteur demeurent obscurs. Dans 
cette optique, l’objectif de cette étude a été d’examiner l’efficacité de la curcumine à inhiber la 
signalisation induite par l’ET-1 dans les CMLV. La curcumine a inhibé la phosphorylation des 
protéines IGF-1R, PKB, c-Raf et ERK1/2, induite par l’ET-1 et l’IGF-1. De plus, la curcumine a 
inhibé l’expression du facteur de transcription Egr-1 induite par l’ET-1 et l’IGF-1, dans les 
CMLV. Ces résultats suggèrent que la capacité de la curcumine à atténuer ces voies de 
signalisation serait un mécanisme d’action potentiel de ses effets protecteurs au niveau 
cardiovasculaire. 
 
Mots-clés : CMLV, Curcumine, Egr-1, ERK1/2, ET-1, IGF-1, IGF-1R, PKB. 
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Abstract 
Cardiovascular diseases (CVDs), including hypertension and atherosclerosis, are 
associated with vascular functional and structural changes. Some of the cellular events underlying 
these processes include aberrant vascular smooth muscle cell (VSMC) proliferation, hypertrophy 
and migration. Endothelin-1 (ET-1) has been implicated in the pathogenesis of vascular 
abnormalities through the hyperactivation of key components of growth promoting and 
proliferative signaling pathways, including MAPKs and PI3-K/PKB. Vascular oxidative stress 
has also been suggested to play an intermediary role in mediating ET-1-induced 
pathophysiological effects. Interference with ET-1-induced signaling may therefore serve as a 
potential therapeutic strategy against the progression of cardiovascular disorders. There is 
presently a surge of interest in the use of plant-derived phytochemicals for the treatment of 
various diseases. Curcumin, the main constituent of the spice turmeric, exhibits multiple 
biological properties, amongst them, antioxidant, anti-proliferative and cardioprotective 
properties. However, the molecular mechanisms of its cardiovascular protective action remain 
obscure. Therefore, in the present studies, we investigated the effectiveness of curcumin to inhibit 
ET-1-induced signaling events in VSMC. Curcumin inhibited ET-1-induced as well as IGF-1-
induced phosphorylation of IGF-1R, PKB, c-Raf and ERK1/2, in VSMC. Furthermore, curcumin 
inhibited the expression of transcription factor early growth response-1 (Egr-1) induced by ET-1 
and IGF-1, in VSMC. In summary, these results demonstrate that curcumin is a potent inhibitor 
of ET-1 and IGF-1-induced mitogenic and proliferative signaling events in VSMC, suggesting 
that the ability of curcumin to attenuate these effects may contribute as potential mechanism for 
its cardiovascular protective response.  
 
Keywords: Curcumin, Egr-1, ERK1/2, ET-1, IGF-1, IGF-1R, PKB, VSMC  
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Cardiovascular diseases (CVDs), including hypertension, atherosclerosis and heart failure, 
are among the most encountered pathologies that affect developed countries. Even though 
significant advances in diagnosis and treatment have been introduced, CVDs remain one of the 
leading causes of mortality and morbidity. Many pathways are implicated in the regulation of 
cardiovascular homeostasis and a variety of factors can contribute to the onset of CVDs. Among 
those factors are two important vasoactive peptides, endothelin-1 (ET-1) and angiotensin II (Ang 
II), that play an important physiological role in regulating vascular tone and blood pressure. 
Alterations in the regulation of these vasoactive peptides can contribute to the pathogenesis and 
progression of numerous CVDs. High levels of ET-1, associated with increased activation of 
growth promoting and proliferative signaling, are present and implicated in several CVDs, 
including hypertension, atherosclerosis and heart failure. Therefore, targeting the ET-1 system 
may be helpful for the management of these conditions and their associated complications. In this 
regard, the last decade has witnessed a surge of interest in investigating the potential role of 
various plant derived substances, such as curcumin that exhibit cardiovascular protective effects. 
Therefore, the objective of this section is to provide a brief overview on the aspects of the ET-1 
system and its contribution to the pathophysiology of CVDs, as well as a brief overview on 
curcumin and its mechanism of action at the molecular level, with particular interest to its role in 
the cardiovascular system. 
1.1. Endothelin 
Endothelin (ET), discovered by Dr. Yanagisawa’s group in 1988 (1), is one of the most 
prominent known vasoconstrictors that also exhibits inotropic, chemotactic and mitogenic 
properties, influences salt and water homeostasis, and stimulates the renin-angiotensin-
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aldosterone as well as the sympathetic nervous systems (1, 2). ET plays a crucial role in 
cardiovascular physiology. The overall physiologic action of ET is to increase vascular tone and 
blood pressure (2). Alteration of this system has been associated with several CVDs (3). These 
events establish ET as a potentially important mediator in the pathogenesis of cardiac, vascular 
and renal abnormalities such as hypertension, atherosclerosis, hypertrophy, and restenosis (4). ET 
exerts its physiological action through the activation of several signal transduction pathways 
linked to cellular hypertrophy, migration and proliferation in several cell types, including 
vascular smooth muscle cells (VSMC) (5). 
1.2 Structure of endothelins  
ET exists as three 21 amino acid isopeptides named ET-1, ET-2 and ET-3. Three 
independent genes, located on chromosome 6, 1, and 20, respectively, encode the three 
structurally and pharmacologically distinct isopeptides (6). A proposed fourth member was later 
shown to be rodent homologue to human ET-2, rather than a truly novel isoform (7). ETs possess 
a great sequence homology with four further peptides, known as sarafotoxins, extracted form the 
venom of a snake, Atractaspis engaddensis (8). All ET isopeptides share a common cyclic 
structure that consists of two disulfide bridges joining the cysteine amino acids (positions 1-15 
and positions 3-11) at the N-terminal end, a cluster of three polar charged side chains on amino 
acid residues 8-10 and a hydrophobic C-terminus containing an aromatic indole side chain at  
Trp21 (Figure 1.1). The C-terminal end contains amino acids that bind to the ET receptor while 
the N-terminal determines peptide affinity to the receptor (9). ET-2 contains two amino acid 
substitutions and shares 90% sequence homology with ET-1. ET-3 contains six amino acid 
substitutions and shares 71% sequence  
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Figure 1.1 Structure of the isoforms of endothelin (ET).  
Endothelin (ET) is a 21 amino acid cyclic peptide with two disulphide bridges joining the 
cysteine residues at positions 1-15 and 3-11. The amino acids highlighted in black represent the 
differences in between ET-2 and ET-3 compared to ET-1.  
(Khimji AK : Cellular Signalling 22: 1615-1625, 2010). 
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homology with ET-1 and ET-2. Amongst the three ETs, ET-1 is regarded as the most prominent 
isoform synthesized by the vasculature (1) and accounts for the majority of the pathobiological 
effects exerted by the ETs (10). 
1.3 ET-1 regulation of generation and sites of generation 
The regulation of ET-1 production is achieved at the transcriptional level of the preproET-1 gene 
(11). ET-1 expression is regulated at the promoter region (5’) of the preproET-1 gene where there 
are binding sites for activator protein 1 (AP-1) and nuclear factor 1 (NF-1) transcription factors, 
which mediate the induction of mRNA for ET-1, through regulation by Ang II and transforming 
growth factor-β (TGF-β), respectively (12-14). Further post-transcriptional modulation occurs 
through selective destabilization of the preproET-1 mRNA via adenine-uracil-rich sequences, 
present in the non-translated 3’ region, accounting for its selectively short biological half life of 
15-20 minutes (15). ET-1 mRNA is upregulated by various stimuli, including vasoactive 
hormones, growth factors, hypoxia, low vascular shear stress, lipoproteins, free radicals, 
endotoxin and cyclosporin (16). However, ET-1 production is downregulated by high shear stress 
and by compounds that increase intracellular levels of cyclic guanosine monophosphate (cGMP), 
such as endothelium-derived nitric oxide (NO), nitrovasodilators, natriuretic peptides, heparin 
and prostaglandins (Figure 1.2) (16). 
Vascular endothelial cells are the main site of ET-1 synthesis (6), which also correlates 
with the high expression levels of mRNA for ET-1 precursor molecule preproET-1 and its 
converting enzyme. VSMC also express ET-1 mRNA, but its production is 100 fold less than that 
of endothelial cells (15). Even in very low concentrations, ET-1 is also  
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Figure 1.2 Factors regulating ET-1 synthesis, pathway of ET-1 generation and ET receptor-
mediated actions on smooth muscle cells.  
ET-1 synthesis is regulated by multiple factors; stimulators are highlighted in green and 
inhibitors in red. The synthesis of ET-1 begins with the transcription product preproET-1 (212 
aa), which is cleaved to form proET-1. Pro-ET-1 undergoes cleavage by a furin-like protease to 
form bigET-1 (38aa) that is converted to mature ET-1 (21 aa) by endothelin converting enzyme-1 
(ECE-1). ET type-A (ETA) receptors are found in vascular smooth muscle cells and mediate 
vasoconstriction and cell proliferation, while ETB receptors reside on endothelial and smooth 
muscle cells and mediate vasodilatation. ANP, atrial natriuretic peptide; BNP, brain natriuretic 
peptide; CNP, C-type natriuretic peptide; TGF-β, transforming growth factor β. (Remuzzi et al: 
Nature Reviews Drug Discovery 1: 986-1001, 2002). 
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produced by the heart, kidney, lung, posterior pituitary and central nervous system (10, 16, 17). 
In the cardiovascular system, ET-2 and ET-3 are expressed at very low levels. 
1.4 Biosynthesis of ET-1 
Several processing steps are required before the mature ET-1 peptide is formed (Figure 
1.2). ET-1 synthesis begins with the transcription of the preproET-1 gene. The translation of the 
preproET-1 mRNA yields a large 212 amino acid precursor molecule, preproET-1. The latter is 
converted to proET-1 through the removal of its signal sequence and secreted into the cytoplasm 
(2). ProET-1 then undergoes a proteolytic cleavage at dibasic sites by a furin-like protease to 
form a biologically inactive 38 amino acid peptide, bigET-1 (18). BigET-1 is cleaved between 
Trp21 and Val22, in the rate limiting step in ET-1 synthesis, by the ET-converting enzyme-1 
(ECE-1) metalloproteinase to yield the mature 21 amino acid bioactive ET-1 peptide (9). ET-1 
has been known to be synthesized in a constitutive de novo manner and mature ET-1 is directly 
released into the bloodstream (11). Evidence suggests that in certain cells it is also secreted via 
pathways involving secretory granules (19). In fact, secretory vesicles containing both mature 
ET-1 and ECE have been identified in endothelial cells (20).  ET-1 secretion by endothelial cells 
occurs in a polar manner, where most of ET-1 is secreted on the basal side, resulting in 100 fold 
higher concentrations within the vascular wall compared to plasma levels (21).  Thus, under 
normal physiological conditions, ET-1 is not a circulating hormone but rather a locally-acting 
autocrine/paracrine factor (10). 
1.5 Bioavailability and clearance of ET-1  
In healthy subjects, the circulating concentrations of ET-1 in venous plasma are in the 
range of 1-10pmol/L (15). Circulating concentrations of ET-1 are lower than those which cause 
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vascular constriction in vitro and in vivo, although concentrations at the interface between an 
endothelial cell and VSMC are likely to be higher (15). Indeed, endothelial cells secrete 
substantially more ET-1 towards VSMC than they do luminally (21). Thus, the circulating level 
of ET-1 might not directly reflect the full physiological impact of ET-1. Venous plasma ET-1 
concentrations of bigET-1 and C-terminal fragments, when they are cleaved by ECE-1, appear to 
reflect generation of ET-1 more accurately (22). The low plasma levels of ET may be related to 
rapid elimination from the bloodstream. 
 ET levels are controlled by continuous metabolism/clearance. Clearance of ET-1 from 
circulation is very rapid, and its biological half life is about 1 minute, owing to its efficient 
extraction in the pulmonary and renal vascular beds (23). This extraction involves binding to the 
cell surface ETB receptors, followed by internalization and degradation, probably within 
lysosomes (24). ETs are also degraded by neutral endopeptidases found in kidney proximal 
tubules (24). The liver is also a site of ET-1 clearance (25). On the contrary to its rapid 
elimination, its biological effects last considerably longer, possibly due to the almost irreversible 
binding of ET-1 to its receptor (26). For instance, its pressor effects are sustained for up to an 
hour (27) and it has been shown that ET-1 remains associated with ET receptor up to two hours 
after endocytosis (28). 
1.6 ET-1 receptors 
ET-1 exerts its biological effects in a paracrine/autocrine fashion through the activation of 
its receptors. Two main ET receptor subtypes, ETA and ETB, have been cloned in humans (29, 
30). These receptors belong to the rhodopsin class A of seven transmembrane guanine 
nucleotide-binding protein-coupled receptors (GPCRs), which stimulate cellular events by 
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activation of heterotrimeric guanine nucleotide binding proteins (G proteins). They contain seven 
transmembrane domains of 22-27 hydrophobic amino acids in their estimated 400-amino acid 
sequences with an N-terminal extracellular region and C-terminal intracellular region (29, 30). 
Each receptor is capable of coupling to different G protein families. ETA and ETB receptors share 
59% polypeptide sequence identity and are encoded by distinct genes located on chromosomes 4 
and 13, respectively (31, 32). ET-1 receptors have different molecular and pharmacological 
characteristics and exhibit somewhat different physiological roles based on their location. ETA 
receptors contain 427 amino acids (31) and are predominantly expressed in VSMC but are also 
found in cardiomyocytes, fibroblasts, hepatocytes, adipocytes, osteoblasts and brain neurons (29, 
33), and exhibit higher affinity for ET-1 and ET-2 than for ET-3 (29). ETB receptors contain 442 
amino acids (31) and are predominantly expressed in endothelial cells, however, a relatively low 
level of expression in other cells including VSMC, cardiomyocytes, hepatocytes, fibroblasts, 
osteoblasts, different types of epithelial cells and neurons has been reported (30). ETB receptors 
have equal subnanomolar affinities for all ET peptides (30). 
Stimulation of ETA and ETB receptors elicits diverse physiological responses. ET-1 
binding to ETA and ETB receptors on VSMC produces vasoconstriction, cell growth and cell 
adhesion (18). Conversely, ET-1 binding to endothelial ETB receptors causes vasorelaxation 
through the release of vasodilators acting on VSMC, prevents endothelial cell apoptosis, inhibits 
ECE-1 expression within endothelial cells and is involved in ET-1 clearance (18). Thus, the net 
effect produced by ET-1 on the vasculature is determined on the receptor localization and the 
balance between ETA and ETB receptors. 
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1.7 Biological actions of ET-1 in the cardiovascular system 
In the vasculature, ET-1 is involved in the basal vascular tone regulation. It induces a 
biphasic response represented by a transient vasodilatation followed by a sustained 
vasoconstriction. Endothelial cell ETB receptors mediate vasodilatation through the production of 
endothelium-derived vasodilators, such as NO and prostacyclin, before the development of 
sustained vasoconstriction. Vasoconstriction is mediated by ET-1 activation of ETA and ETB 
receptors located on VSMC. The prolonged vasoconstriction is not dependent on ET-1 plasma 
levels but rather on the slow dissociation from its receptors (34). The vasoconstrictor effect is 
selective for some vascular beds. In animals, the coronary and renal vascular beds exhibit higher 
vasoconstriction to systemic administration of ET-1 (35). Systemic administration of ET-1 in 
humans induces sustained vasoconstriction in coronary vessels (36), but also causes renal and 
splanchnic vasoconstriction (37, 38). The differences among beds may be related to the balance 
between ETA and ETB-mediated effects. 
ET-1 has been also shown to increase blood pressure in vivo in both animals and humans. 
In animals, bolus administration and intravenous infusion of ET-1 increased arterial pressure and 
this effect lasted for at least one hour before arterial pressure returned to base-line levels (39). In 
humans, intravenous infusion of ET-1 increased blood pressure in healthy volunteers (36, 40). 
Bolus administration of ET usually causes a preceding transient hypotension, which is mostly 
marked for ET-3 (6) and is mediated by endothelin ETB receptors. This does not occur when ET 
concentrations rise more slowly, which is more likely to represent physiological conditions (39). 
ET-1 is also synthesized in the heart by cardiomyocytes, cardiac fibroblasts and cardiac 
endothelial cells (41). The reported biological effects of the ET system on the healthy heart are 
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mainly positively inotropic in association with a negative lusitropic effect (33), positively 
chronotropic and hypertrophic (42). However, the ET system is upregulated in chronic heart 
failure, and ET-1-induced sustained coronary vasoconstriction may result in the deterioration of 
cardiac function causing myocardial ischaemia leading to fatal ventricular arrhythmias and 
cardiac hypertrophy (43, 44). Under such conditions, ET-1 exerts systemic and coronary 
vasoconstriction leading to increased afterload and reduced cardiac output (45). ET-1 induces 
cardiac hypertrophy, through its mitogenic properties, as an adaptational mechanism to stresses 
such as pressure overload (46-48).  
ET-1 also exerts long-term effects in the vasculature, such as vascular remodeling, by 
promoting smooth muscle proliferation (49), protein synthesis (50), and production of a variety 
of cytokines (51) and growth factors (52). ET-1 also potentiates the mitogenic effects of growth 
factors such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and basic 
fibroblast growth factor (bFGF) and is considered as a co-mitogen with these growth factors (53).  
1.8 Role of ET-1 in cardiovascular diseases 
Dysregulation of the ET system is significantly involved in the development of 
cardiovascular pathologies, such as hypertension, atherosclerosis, cardiac hypertrophy, 
congestive heart failure and coronary artery disease, as well as CVDs linked to diabetes, 
pulmonary hypertension, pulmonary fibrosis, kidney failure and other important processes. ET-1 
is believed to play a role in vascular remodeling associated with experimental and human 
hypertension (54). ET receptor antagonists that have been developed help to investigate the role 
of ET-1 in CVDs (48). 
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1.8.1 ET-1 in hypertension 
1.8.1.1 ET-1 in experimental hypertension  
Evidence of pressor action of ET-1 has led to the speculation that ET-1 is involved in the 
pathogenesis of hypertension (1). In fact, ET-1 plasma levels are found to be significantly 
increased in certain animal models of hypertension (55). Deoxycorticosterone acetate (DOCA) 
salt-hypertensive rats, DOCA salt-treated spontaneously hypertensive rats (SHR), Dahl salt-
sensitive rats, Ang II-induced hypertension, 1-kidney 1-clip Goldblatt hypertensive rats, and 
stroke-prone SHR are all experimental models of hypertension that exhibit an increase in 
systemic levels of ET-1. The increased production of vascular ET-1 in these hypertensive models 
is associated with hypertrophic remodeling of resistance arteries, and a response to both selective 
and mixed ET receptor antagonism resulted in a reduction in blood pressure as well as a 
regression of vascular growth (55). ET-1 has been shown to activate nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase and increase reactive oxygen species (ROS) 
production in VSMC, in blood vessels and in hypertensive rats (56, 57). The growth-promoting 
remodeling action of ET-1 may be partly mediated by this increase in ROS production (58). In 
aldosterone-induced hypertension, systolic blood pressure, ET-1 plasma levels, systemic 
oxidative stress, and vascular NADPH activity in association with small artery hypertrophic 
remodeling was increased (59). However, all these aberrant parameters were normalized in this 
model by treatment with ETA receptor antagonist (59). 
ET-1 is involved in renal and cardiac target organ damage in hypertension. An increase in 
renal ET-1 in hypertensive rats is involved in renal fibrosis through the activation of growth 
factors and by inducing inflammation (60). These events were normalized when treated with a 
selective ETA receptor antagonist, and kidney function was restored (60). Rats made hypertensive 
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through exogenous ET-1 infusion showed changes in renal function, and signs of oxidative stress 
that were reduced by a free radical scavenger further imply a role of ROS in this process (61). In 
the heart, ETA receptor (62), ETA/ETB receptor (63) and ECE antagonists (64) prevented target 
organ damage in hypertensive animal models. Blockade of the ET system in transgenic mice with 
inducible malignant hypertension prevented an increase in cardiac ET-1 concentrations, 
suggesting that ET receptor blockade may provide as a protecting tool against hypertensive 
cardiac damage (65).  It should, however, be noted that all animal hypertensive models are not 
the same, and that different hypertensive diseases have different etiologies in which ET-1 plays a 
different role within each form of hypertension. 
1.8.1.2 ET-1 in essential hypertension 
The hallmark of hypertension is an increase in peripheral vascular resistance displayed by 
increased vascular tone of small arteries and vascular remodeling (66, 67). In comparison to 
normotensive patients, there is no significant change in plasma concentrations of ET-1 in 
hypertensive patients from studies that have investigated the role of ET-1 in essential 
hypertension (54).  As such, plasma concentrations of ET-1 do not reflect the presence of 
essential hypertension, presumably due to the fact that ET-1 is generated and is biologically 
active in a paracrine and/or autocrine manner.  Increases in ET-1 levels seem to be related to age, 
smoking and renal dysfunction rather than to hypertension (68). However, in certain ethnic 
groups, such as African American hypertensive subjects, increased plasma ET-1 levels have been 
observed (69). Interestingly, increased preproET-1 is found in the endothelium of small arteries 
of patients with moderate-to-severe hypertension (70) and enhancement of ET-1 generation plays 
a role in hypertrophic signaling in these patients (70). Increased ET-1 messenger and protein 
levels in VSMC cause the formation of larger elastic and muscular arteries of hypertensive 
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patients (71). Increased ET system activity has been suggested in patients with hypertension in 
comparison to normotensive patients. This is based from studies where ETA receptor antagonism 
causes vasodilation in forearm vessels of essential hypertensive patients compared with 
normotensive subjects (72). Conversely, ETB receptor antagonism induced vasoconstriction on 
forearm resistance arteries in normotensive patients (73) and is shown to have a vasodilator 
action on hypertensive subjects (73), indicating a vasoconstricting effect of ETB receptors in 
hypertensive but not in normotensive states. African Americans appear to have an increased 
expression of VSMC ETB receptors that might mediate the ET-1 response (69). Other studies 
have investigated a long-term antihypertensive effect of ET receptor antagonism. A four-week 
treatment with ETA/ETB receptor antagonist, bosentan, significantly lowered diastolic pressure in 
a study with 293 patients with mild-to-moderate essential hypertension (74). Darusentan, a 
selective ETA receptor antagonist, also significantly reduced systolic and diastolic blood pressure 
in human hypertension (75). 
1.8.2 ET-1 in atherosclerosis 
In addition to its effects on blood pressure, ET-1 is pro-inflammatory and is implicated in 
the development of atherosclerosis (76). Evidence supporting a role for the effect of ET-1 in the 
pathogenesis of atherosclerosis comes from data supporting that ET-1 and its receptor levels are 
elevated in experimental models of atherosclerosis (77, 78), and in human coronary artery 
atherosclerotic plaques (79). Additionally, ECE-1 has been shown to be upregulated in VSMC 
and in macrophages from atherosclerotic plaques (80). Further evidence is demonstrated in 
experiments showing that ETA receptor antagonism inhibits the formation of early atherosclerotic 
lesions in hyperlipidaemic hamsters, by decreasing the number and size of macrophage-foam 
cells (81), suggesting a pro-inflammatory role of ETA activation. ETA receptor antagonism also 
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reduced the development of atherosclerosis in apolipoprotein E (ApoE) deficient mice, an animal 
model for atherosclerosis (82). Bosentan inhibited neointimal development in collared carotid 
arteries of rabbits, another known model of atherosclerosis (83). Bosentan also significantly 
attenuated the development of graft atherosclerosis in rat cardiac allografts (84). In humans, 
infusion of selective ETA receptor antagonist BQ123, improves coronary vascular function in 
patients with atherosclerosis (85).  
ET-1 has been associated with the development of atherosclerosis mainly through its 
actions on VSMC. ET-1 stimulates VSMC proliferation (86), migration (87), contraction (88), 
matrix remodeling (89), synthesis of extracellular matrix (90) and the expression of other pro-
atherogenic growth factors such as PDGF and TGF-β (91). 
1.8.3 ET-1 in heart failure 
Circulating ET levels have been shown to be increased in both experimental and human 
heart failure (92, 93). ET-1 is proposed to contribute to acute and chronic increases in vascular 
resistance, ventricular and vascular remodeling, inflammation, and arrhythmogenesis in models 
of heart failure (94). ET-1 stimulates the secretion of other neurohormones and potentiates their 
effects, resulting in long-term effects on the heart and contribution to the progression of chronic 
heart failure (CHF) (47). The gene expression of ET-1 precursor and ECE-1 is up-regulated four 
and three-fold respectively, in the failing human heart (95). This increase is attributed to the 
production from cardiac as well as extra-cardiac tissues such as the lungs (93). The increased 
levels of ET-1 correlate with haemodynamic severity and symptoms (96, 97). Evidence is 
accumulating mostly from animal studies, that ET receptor antagonism can ameliorate the 
deleterious haemodynamics and structural changes associated with heart failure.   
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ETA receptor antagonism in hamsters with CHF and in rat coronary ligation models 
improves their survival (98, 99). In heart failure in dogs, bosentan decreased aortic pressure and 
increased stroke volume (100). Dual ET receptor antagonist TAK-044 and ETA receptor 
antagonist FR 139317 also decreased cardiac pressures, and increased cardiac output (101). In a 
pig model of CHF, combined Ang II receptor blockade with bosentan resulted in greater 
improvement of ventricular function (102). Recently, it has been shown in an acute model of rat 
heart failure that myocardial contractility was restored and cardiac relaxation significantly 
improved after application of PP36, an inhibitor of ECE, suggesting a crucial role of ET 
production in this pathophysiological state (103). 
In clinical trials, short term administration of bosentan or ETA receptor antagonist 
LU135252 exhibited beneficial haemodynamic effects of patients suffering with CHF (104-106). 
In another clinical trial, intravenous infusion of the dual ET receptor antagonist tezosentan 
rapidly and effectively improved haemodynamics in patients suffering from acute decompensated 
heart failure (107). Despite these results and the clear rationale for the use of ET antagonists in 
heart failure, human clinical trials have generally not been proven to be very effective. The 
beneficial haemodynamic effects have been found to be short lived and treatment with ET 
antagonists has been associated with adverse side effects, including hypotension and abnormal 
liver function (108, 109). 
1.9 ET-1-induced signaling in vascular smooth muscle cells 
ET-1 exerts its physiological actions through the activation of multiple signaling 
pathways which include the PLC/DAG/IP3, MAPKs and PI3-K/PKB pathways. Receptor and 
non-receptor tyrosine kinases also play a role in mediating ET-1-induced signaling events. The 
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cellular events triggered by the activation of these pathways are involved in regulating cellular 
growth, proliferation, contraction and survival of VSMC (110).  
1.9.1 Activation of the phosphoinositide cascade by ET-1 in VSMC 
The binding of ET-1 to its receptor induces a conformational change in the heterotrimeric 
G protein, that consists of an α, β and γ-subunit (111). In its inactive form, the α-subunit is ligated 
to guanosine diphosphate (GDP) but when activated, GDP is exchanged for guanosine 
triphosphate (GTP), causing the α-subunit to dissociate from the βγ dimmer complex, while they 
all remain associated to the membrane (111). Activation of the Gα subunit following ET-1 
binding to its receptor initiates downstream G-protein signaling. This leads to the activation of 
phosphoinositide-specific phospholipase C β (PLC β), which then hydrolyzes the membrane 
phospholipid phosphatidylinositol-4’-5’-biphosphate (PIP2) to generate two second messengers: 
hydrophobic diacylglycerol (DAG), and soluble inositol-1’,4’,5’-triphophate (IP3) (112). IP3 
stimulates the release of calcium (Ca2+) from intracellular stores, which plays an important role in 
regulating the contractile response of the cell (113). DAG, together with Ca2+, activate the 
phosphatidylserine-dependent protein kinase, protein kinase C (PKC) (114) (Figure 1.3). 
 PKC is a family of serine/threonine kinases, comprised of 12 currently identified isoforms (114) 
that translocate from the cytosol to the cell membrane, where they become activated and 
phophorylate several cytosolic proteins (115). Many studies have implicated PKC in deleterious 
vascular effects of several pathologies including diabetes and hypertension (116). Growing 
evidence suggest that ET-1-induced activation of PKC in VSMC leads to protein synthesis (117), 
cellular proliferation (115, 118) and contraction (119). Thus, ET-1-induced activation of PKC 
and its downstream effects appears to be important in regulating vascular function. 
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1.9.2 ET-1-induced activation of MAPK cascade in VSMC 
Downstream of PKC, ET-1 receptor activation also results in stimulation of mitogen 
activated protein kinase (MAPK) cascades. MAPK are a family of serine/threonine protein 
kinases which are classically associated with cell growth, proliferation, differentiation, death, and 
contraction (120, 121). Extracellular signal-regulated kinase 1 and 2 (ERK1/2), p38 MAPK and 
c-Jun N-terminal kinases (JNK) are the main groups of MAPKs. These MAPK all follow a 
similar system of sequential activation by several upstream signaling components, in which a 
stimulus activates a MAPKKK, which will then phosphorylate and activate a MAPKK, which 
will at last phosphorylate Thr and Tyr residues in the activation loop of the final effector, MAPK, 
leading to its activation and hence cellular response.  ET-1 activates JNK and p38 cascades but to 
a lesser degree than ERKs in VSMC (122). Signals from GPCR to ERK1/2 are transmitted via 
Ras, a small membrane-bound GTP-binding protein. Ras cycles between an active GTP-bound 
conformation and inactive-GDP-bound  
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Figure 1.3 Schematic model showing the activation of ERK1/2 and PI3-K/PKB signaling 
pathways through IGF-1R phosphorylation by ET-1 in VSMC.  
ET-1 receptor stimulation leads to both Gqα, as well as βγ activation, which in turn activate PLC 
β. PLC β converts PIP2 to IP3 and DAG. IP3 is responsible for elevating intracellular Ca2+ 
concentrations. DAG activates PKC. Through the activation of several downstream 
intermediates, Ca2+ alone or in partnership with PKC or other intermediates triggers the 
activation of NR-PTKs, by inducing their phosphorylation on target tyrosine residues. Activation 
of these PTKs leads to the phosphorylation of docking proteins, such as IRS-1, which serve as 
docking sites for Grb-2/SOS. The latter can lead to activation of Ras/Raf/MEK/ERK1/2 pathway. 
Phosphorylated IRS-1 activates PI3-K which goes on to catalyze the phosphorylation of PIP2 to 
PIP3, allowing PKD-1/2 recruitment to the plasma membrane, where PDK-1/2 will 
phosphorylate PKB on threonine and serine residues.  ET-1 also increases ROS generation by 
activating NADPH oxidase, through an unknown mechanism, in VSMC. Endogenously produced 
ROS are able to inhibit PTPases through the oxidation of cysteine residues in its catalytic 
domain. Inhibition of these PTPases favours tyrosine phosphorylation of NR-PTKs and R-PTKs, 
resulting in the ligand-independent activation of R-PTK, such as IGF-1R, that act upstream of 
Ras/Raf/MEK/ERK1/2 and PI3-K/PKB pathways. Activation of ERK1/2 and PKB signaling 
cascades plays a role in mediating various cellular responses such as gene transcription, protein 
synthesis, cell growth and cell survival. 
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form (120). Activated Ras recruits and activates Raf, a MAPKKK, that phosphorylates MEK, a 
MAPKK, at specific serine/threonine residues, which in turn phosphorylates ERK1/2 in threonine 
and tyrosine residues (120). Chen et al. have reported an implication of PKC in ET-1-induced 
ERK activation through ETA receptors in human VSMC (123). Activation of ERK1/2 leads to the 
phosphorylation of downstream cytosolic target substances on serine and threonine residues. 
ERK1/2, along with other MAPK family members, can also be translocated from the cytosol to 
the nucleus where they can phosphorylate and activate several transcription factors which lead to 
the activation of genes involved in cell growth and differentiation (120) (Figure 1.3). 
Several reports have demonstrated that ET-1 activates ERK1/2 signaling pathways in 
cardiomyocytes (124), fibroblasts (125), glomerular mesangial cells (126) and VSMCs (5). 
Activation of ERK1/2 can potentially result to an increased proliferation and hypertrophy of 
VSMC in response to ET-1 given that inhibition of its upstream mediator, MEK1/2, resulted in 
inhibition of ET-1-induced DNA and protein synthesis (127, 128).  
1.9.3 ET-1-induced phosphatidylinositol-3-kinase cascade activation in 
VSMC 
Phosphatidylinositol-3-kinases (PI3-K) are a family of lipid kinases that have emerged as 
important effectors of ET-1 action (110). PI3-K phosphorylates the 3’ position of the inositol ring 
of the membrane-bound phosphoinositides, phosphatidylinositol (PI), PI 4-phosphate, and PI 4,5-
phosphate. This reaction generates biologically active lipids PI 3-P, PI 3,4-biphosphate 
(PI(3,4(P2) and PI(3,4,5)triphosphate (PI(3,4,5)P3), respectively (129). These phospholipids act as 
second messengers to activate several protein kinases such as PI(3,4,5)P3 dependent protein 
21 
 
 
kinase (PDK), protein kinase B (PKB) and 70kDa ribosomal protein S6 kinase (p70S6K) (129) 
(Figure 1.3). 
PI3-Ks are divided into three classes based on their substrate specificity, molecular 
structure and mode of regulation (129). Class I PI3-Ks generates PI(3)P, PI(3,4)P2, PI(3,4,5)P3 
and are activated by receptor protein tyrosine kinases (R-PTK) and GPCRs (129). Class II PI3-Ks 
generate PI(3)P, PI(3,4)P2, and possess a lipid binding domain, whereas, class III PI3-Ks only 
generate PI(3,4,5)P3 (129). Class I PI3-Ks are further subdivided into class IA and IB PI3-Ks and 
are heterodimeric proteins composed of a catalytic and regulatory subunit. Class IA proteins 
consist of a 110 kDa (p110) catalytic subunit and an associated 85 kDa (p85) regulatory subunit. 
Class IA has three isoforms of the catalytic subunit, p110α, p110β and p110δ, and several 
isoforms of the regulatory subunit, p85α, p55α, p50α, p85β and p55γ. In contrast to class IA, 
class IB has only one catalytic member, p110γ, and one form of the regulatory subunit, p101. The 
class IA PI3-Ks are activated by R-PTK, while class IB is activated by GPCR (130). 
The PI3-K pathway plays a pivotal role in cell migration, differentiation, proliferation and 
survival (130). Several studies have reported an involvement of PI3-K as an upstream mediator of 
several ET-1 induced responses. However, except for rat glomerular mesangial cells, where ET-
1-induced PI3-K activation is necessary for hypertrophy (131), no direct activation of PI3-K by 
ET-1 in VSMC has been documented. However, the PI3-K inhibitor wortmannin has been shown 
to have an inhibitory effect on ET-1-stimulated cell proliferation and protein synthesis in A-10 
VSMC (127, 128). 
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1.9.4 ET-1-induced PKB activation in VSMC 
Several downstream targets of PI3-K have been documented, the most studied being PKB, 
also known as Akt (a product of akt proto-oncogene). PKB is a 57 kDa serine/threonine kinase 
with three identified isoforms in the mammalian system, PKBα/Akt1, PKBβ/Akt2 and 
PKBγ/Akt3 (132). All isoforms possess an N-terminal pleckstrin homology (PH) domain that 
binds to phospholipids generated by PI3-K, a central catalytic kinase domain with specificity for 
serine or threonine residues on substrate proteins, and a C-terminal regulatory domain containing 
a hydrophobic motif (132). Full activation of PKB is a sequential two step process where the 
lipid products generated from PI3-K are recognized by the PH domain of PKB, translocating it to 
the plasma membrane, where it then gets phosphorylated on Thr308 by PDK-1 and on Ser473 by 
a putative kinase termed PDK-2 for its complete activation (133) (Figure 1.3). Phosphorylation of 
both sites is mitogen-and PI3-K-dependent (133). 
PKB has been shown to promote a variety of cellular responses including inhibition of 
apoptosis and promotion of cell survival, regulation of cellular proliferation, metabolism and 
hypertrophy (132). PKB substrates include members of cell survival and apoptosis cascade such 
as Bcl-2, BAD (134, 135), caspase-9 (136) and glycogen synthase kinase-3 (GSK-3) (137), as 
well as regulators of protein synthesis and cell growth such as mammalian target of rapamycin 
(mTOR) (138). ET-1 has been shown to activate PKB in cardiomyocytes (139), myofibroblasts 
(140), human umbilical vein endothelial cells (141) and A-10 VSMC (5, 127, 128).  
1.10 ET-1-induced growth factor transactivation 
Recent findings suggest that ET-1 and other vasoactive peptides, such as Ang II, whose 
receptors belong to GPCR family, stimulate intracellular signaling pathways through 
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transactivation of R-PTK, and thereby mediate the ERK1/2 and PKB signaling events. Among 
the main growth factor receptors implicated in this process, epidermal growth factor receptor 
(EGF-R), insulin–like growth factor type 1 receptor (IGF-1R) and platelet derived growth factor 
receptor (PDGF-R) have been investigated in some detail. EGF-R has been studied in some detail 
in response to Ang II and ET-1 (142, 143), as has PDGF-R in response to Ang II (144). However, 
only a few recent studies have investigated the involvement of IGF-1R. 
1.10.1 Role of IGF-1R 
The IGF-1R is a member of the tyrosine kinase class of growth factor receptors that 
shares structural and functional homology with the insulin receptor (IR). Human IGF-1R is a 
ubiquitously expressed product of a single-copy gene located on chromosome 15 (145). The IGF-
1R is a transmembrane heterotetrameric structure that is comprised of two extracellular ligand-
binding α-subunits that are linked by disulfide bonds to each other and to the two transmembrane 
β-subunits that contain intrinsic tyrosine kinase activity, which is believed to be essential for 
most of the receptors biological effects (145). Binding of the ligand to the α-subunit induces a 
conformational change, leading to the activation of the protein tyrosine kinase (PTK) domain of 
the IGF-1Rβ subunit that responds by trans-autophosphorylation of a cluster of tyrosine residues 
within the IGF-1Rβ to provide docking sites for effector proteins (145). Once these residues 
become phosphorylated, the intrinsic PTK activity of IGF-1R is enhanced, thus leading to the 
phoshorylation of several adaptor/scaffolding proteins, including insulin receptor substrate (IRS-
1 or IRS-2) and Src homology collagen (Shc) (146). IRS-1 contains multiple tyrosine 
phosphorylation sites that recognize and bind to SH2 domain-containing signaling molecules, 
such as Grb2, Nck, the p85 subunit of PI3-K, and the SH2 domain-containing tyrosine 
phosphatase-2 (SHP-2) (147). Of these, the binding of Grb2 associated with SOS, a guanine 
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nucleotide exchange factor, to the tyrosine-phosphorylated IRS-1 activates Ras and initiates 
sequential phosphorylation that leads to the activation of ERK1/2 (148). Shc can also interact 
with IGF-1R, in an IRS-1-independent manner (149), to recruit the Grb2/Sos complex and 
activate Ras/Raf/MEK/ERK pathway (148). IGF-1R activation also leads to the activation of PI3-
K/PKB pathway. Tyrosine-phosphorylated IRS-1 interacts with the p85 subunit of PI3-K, leading 
to the activation of the catalytic p110 subunit and to the subsequent activation of the downstream 
substrate PKB (reviewed in (150)). 
In VSMC, a requirement of IGF-1R activity has been recently shown in ET-1-induced 
PKB phosphorylation. These studies demonstrate that ET-1 was able to phosphorylate tyrosine 
residues on IGF-1R β subunit and that use of AG1024, a selective pharmacological inhibitor of 
IGF-1R-PTK activity, attenuated IGF-1R and PKB phosphorylation, as well as protein and DNA 
synthesis induced by ET-1 (151). These results suggest an important role of IGF-1R in mediating 
PKB phosphorylation, as well as hypertrophic and proliferative responses induced by ET-1 in 
VSMC. The mechanism by which ET-1 induces IGF-1R transactivation is not fully understood. 
However, a potential role of ET-1-induced ROS generation in this process has been suggested 
since H2O2 and subsequent inhibition of PTPase have shown to contribute to the activation of 
IGF-1R-PTK in VSMC further resulting in activation of PKB (152, 153) (Figure 1.3).  
1.11 ROS and ET-1 signaling 
ROS are very small, rapidly diffusible, highly reactive molecules that take part in 
physiological reactions and signal transduction but an excessive synthesis can overcome 
antioxidant mechanisms and generate deleterious effects, often resulting in the development of 
CVDs (11). This is in part due to their physicochemical properties which allow them to disrupt 
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biological macromolecules such as lipids, DNA, carbohydrates and proteins. Hydrogen radicals 
(OH˙), superoxide anions (O2˙-), hydrogen peroxide (H2O2), reactive nitrogen radicals and its 
derivative peroxynitrite (ONOO-) are amongst the most important ROS. They are generated both 
enzymatically and non-enzymatically by nearly every cell type including VSMC and endothelial 
cells (11). 
ROS are potent stimulators of ET-1 synthesis in endothelial cells (154) and in human 
VMSC (155). Alternatively, studies demonstrate that ROS can be generated in response to ET-1. 
In fact, ET-1 has been shown to activate NADPH oxidase within several cell types, including 
VMSC (5, 156) and that in vivo, free radicals generated by ET-1 play important roles in 
mineralocorticoid-induced hypertension (57, 157). Both the pressure and vasoconstrictive effect 
of ET-1 were diminished in parallel with the normalization of O2˙- levels after treatment of 
DOCA-salt rats with ETA receptor antagonist (57).  
Increased ROS generation promotes cell growth and proliferation, and is therefore 
associated with a variety of cardiovascular pathologies, including hypertension and 
atherosclerosis (158). The elevated levels of ET-1 during hypertension and atherosclerosis lead to 
excessive production of oxidative stress and a decrease in antioxidant status (159). The 
involvement of ROS in ET-1-induced activation of MAPKs including JNK, p38mapk and 
ERK1/2 has been demonstrated in cardiac fibroblasts (125). Moreover, a role of ROS in ET-1-
induced activation of ERK1/2 and PKB signaling has been demonstrated in VSMC (5) (Figure 
1.3). 
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1.12 Plant-derived cardiovascular protection 
ET-1 is a key player in cardiovascular homeostasis through the activation of the 
previously mentioned signaling pathways, and though this activation is a physiological cellular 
event, aberrant signaling has been implicated in the development and progression of 
pathophysiological events. For instance, upregulation of ET-1-induced signaling through MAPK 
and PI3-K/PKB pathways, particularly in VSMC, is linked to vascular changes observed during 
CVDs such as atherosclerosis and hypertension (160, 161). Many pharmacological interventions 
that have been introduced to target this system failed to show optimal efficacy in diseases other 
than pulmonary hypertension, therefore, interventions are needed to directly target the cellular 
mechanism in order to prevent the effects of ET-1 on VSMC in the development of CVDs. In this 
regard, natural derived products have been extensively researched during the last few decades, 
due to their reported beneficial diverse biological and pharmacological activities on the 
cardiovascular system. Knowledge of traditional medicine has allowed us to identify plants and 
plant-derived substances believed to exhibit such health promoting effects. Plants produce a large 
and diverse array of bioactive substances, known as phytochemicals. These are non-nutritive 
substances that possess health-protective benefits (162). Some of these compounds have been 
shown to exhibit cardiovascular protective effects. Among them, the main constituent of the spice 
turmeric, curcumin, has attracted the attention of scientists and been the subject of their 
investigations. The putative therapeutic properties of curcumin are mainly attributed to its 
antioxidant, anti-inflammatory and anti-carcinogenic properties (163-165). 
1.13 Historical aspects of curcumin 
Curcumin is the main ingredient of the spice turmeric which is an ancient gold-coloured 
spice commonly used in Asiatic countries, mainly India and China, as a culinary ingredient for 
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food flavouring and preservation, as a yellow textile colouring agent, and as a natural remedy for 
medicinal purposes. Turmeric is derived from the rhizomes of the perennial plant Curcuma longa 
Linn, belonging to the Zingiberaceae family, which is distributed in tropical and subtropical 
regions of the world (Figure 1.4). Turmeric contains a wide variety of phytochemicals including 
curcuminoids, a group of polyphenolic compounds that have been shown to deliver beneficial 
effects on health and on events that help in preventing certain diseases. Curcuminoids are mainly 
comprised of three bioactive analogs, curcumin (curcumin I), demethoxycurcumin (curcumin II), 
and bisdemethoxycurcumin (curcumin III) (166) (Figure 1.4). They have all been isolated and 
differ in their methoxy substitution on the aromatic ring.  Curcumin is the most active and 
abundant constituent of turmeric. It is estimated that approximately 2 to 5% of turmeric is 
composed of curcumin (167), while the remainder is made up of mineral matter, carbohydrates, 
proteins, fat and moisture (168). The isolation of pure curcumin is very tedious; consequently, the 
commercially available extracts consist of a combination of the three curcuminoids with 
curcumin as the main constituent (75-81%). Curcumin is responsible for the characteristic yellow 
pigmentation of turmeric and is now acknowledged as being responsible for most of its 
therapeutic effects (167).   
In folk medicine, turmeric and natural curcuminoids have been applied for centuries in 
therapeutic household remedies throughout many parts of the world, particularly in the Orient, 
where it is widely consumed. Its therapeutic use can be traced back to ancient  
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Figure 1.4 Taxonomic position of Curcuma Longa Linn and isolation, extraction and 
structure of parent curcuminoids. (Based on ref (169) and Chattopadhyay et al: Current 
Science 1: 44-53, 2004). 
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Indian and Chinese medicines, where it was used as an anti-inflammatory agent to treat ailments 
associated with abdominal pain, inflammation and pain caused by injury (170). In Ayurvedic 
medicine, it was used against pulmonary disorders, liver disorders, anorexia, rheumatism, 
diabetic wounds, runny nose, cough and sinusitis (171).  
1.14 Chemical properties of curcumin  
Curcumin was first isolated from turmeric in 1815 by Vogel and Pelletier, obtained in 
crystalline structure and identified as 1,6-heptadiene-3,5-dione-1,7-bis(4-hydroxy-3-
methoxyphenyl)-(1E,6E) or diferuloymethane in 1870 by Daube (169). The hydrophobic 
polyphenol feruloymethane skeleton was later elucidated and synthesized in 1910 by J. 
Milodedzka and V. Lampe (169). In chemical terms, it is bis-α, β-unsaturated β-diketone, a linear 
diarylheptanoid compound, where two oxy-substituted aryl moieties are linked together through a 
seven carbon chain (172) (Figure 1.4). The aryl rings may be substituted by hydroxy or methoxy 
groups to produce analogues of curcumin or curcuminoids. It exhibits keto-enol tautomerism and 
in solution it exists predominantly in the enolic form, which is the more stable form (173). In 
neutral and acidic aqueous solutions, the keto form dominates (174). Curcumin has a molecular 
weight of 368.37g/mol, a melting point of 183oC, and its molecular formula is C21H20O6. It is 
insoluble in water or aqueous solvents but soluble in organic solvents such as dimethyl sulfoxide, 
methanol, ethanol and acetone. Spectrophotometrically, curcumin has a maximum absorption in 
methanol at 430nm and it absorbs maximally at 415 to 420nm in acetone, and a 1% solution of 
curcumin has 1650 absorbance units (175). It has a bright yellow colour at pH 2.5 to 7 and takes 
a red hue at pH higher than 7 (175).  
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1.15 Curcumin bioavailability, metabolism, biotransformation and 
pharmacokinetics 
The bioavailability of curcumin is limited by a number of factors, which may be an 
obstacle to its utility as a therapeutic agent. Once absorbed, polyphenolic compounds can directly 
undergo conjugation reactions, predominantly methylation, glucuronidation, and sulfation (176). 
Based on animal studies, poor gastrointestinal absorption, poor water solubility, molecular 
instability, and rapid and efficient metabolism, mainly by the liver and intestine into metabolites 
that are rapidly excreted, are a combination of reasons that contribute to the notion that curcumin 
exhibits poor systemic bioavailability (177, 178). In order to enhance its bioavailability, the co-
administration of curcumin with piperine or its complexation with phospholipids, liposomes and 
micelles has been proposed. Adjuvant co-administration prevents its rapid metabolism by 
interfering with enzymes that catalyze the metabolism of curcumin, while liposomes, micelles 
and phospholipid complexes can reduce the hydrophobicity of curcumin and increase the 
permeability of membrane barriers (166). Other strategies include employing nanoparticle 
technology providing easier penetration through membrane barriers because of their small size 
(166). 
Data on the pharmacokinetics, metabolites, and systemic bioavailability of orally 
administrated curcumin in humans, provided from trials mainly conducted on cancer patients, 
showed that after oral administration of curcumin, no curcumin excretion was detected and that 
serum concentration peaks observed at one to two hours were undetectable at twelve hours (179). 
However, most curcumin conjugates produced by in vivo human metabolism are detectable in 
plasma at greater concentrations than free curcumin with a peak after four hours of dosing (180). 
Although, it has not yet been established if these metabolites are as bioactive as their parent 
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compound, some curcumin metabolites, such as the reduction metabolite tetrahydrocurcumin, 
have been shown to be biologically active in some systems (163).  
An important feature of curcumin is that despite being consumed daily for centuries, it has 
not been shown to cause any toxicity (172). Clinical trial results show that curcumin is well 
tolerated, even at high doses, where it appears non-toxic to animals or humans (179, 181). In 
human trials, only minor side effects of curcumin, namely diarrhoea, have been reported (182). 
These trials however have examined the short term outcome. There is some evidence that long-
term high-dose curcumin administration in rodents can be tumourigenic (183). It has also been 
shown that curcumins predominant activity changes from antioxidant to pro-oxidant with 
increasing concentration (184). 
1.16 Biological actions of curcumin  
Curcumin has been demonstrated to have a wide range of beneficial effects through its 
most pronounced properties which encompass its anti-inflammatory, antioxidant and anti-
carcinogenic activities (177). Modern science has revealed that curcumin is a highly pleiotropic 
molecule that mediates its effects by modulation of several important molecular targets, including 
transcription factors, enzymes, growth factors and their receptors, cell cycle proteins, cytokines, 
cell surface adhesion molecules, and genes regulating cell proliferation and apoptosis (185). 
However, the cellular and molecular mechanisms of the favourable effects of curcumin on human 
health are not fully understood.  
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1.16.1 Anti-inflammatory properties of curcumin  
Most chronic illnesses are believed to be caused by dysregulated inflammation (186). For 
instance, inflammation is involved in cancer, cardiovascular diseases, pulmonary diseases, 
metabolic diseases and neurological diseases (187-191). Although, the mechanism of its anti-
inflammatory action remains unclear, curcumin has been shown to negatively modulate several 
pro-inflammatory responses. Several studies have demonstrated that curcumin was able to 
modulate the production of various inflammatory cytokines, thereby exhibiting potent anti-
inflammatory activity. It has been shown to downregulate nuclear factor-κB (NF-κB), a 
transcription factor that plays a critical role in the induction of many pro-inflammatory mediators 
involved in chronic and acute inflammatory diseases and various cancers (186). Aggarwal and 
Singh were the first to demonstrate that curcumin suppressed NF-κB activation induced by 
different inflammatory stimuli (192), resulting in the suppression of NF-κB-dependent gene 
products that suppress apoptosis and mediate proliferation, invasion, and angiogenesis (186). The 
downregulation of NF-κB by curcumin results in a decrease in the expression of TNF-α, 
interleukin-1 (IL-1), interleukin-6 (IL-6) (169). Therefore, inhibition of pro-inflammatory 
cytokine production by regulation of transcription factors, such as NF-κB, is a potential strategy 
for controlling inflammatory responses. In addition, curcumin has been reported to inhibit the 
activities of cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) enzymes that are involved in 
generating lipid mediators intimately implicated in inflammation, thereby indicating that the anti-
inflammatory actions of curcumin can also modulate arachidonic acid metabolism (193).  
The nuclear transcription factor early growth response-1 (Egr-1) is implicated in the 
regulation of a number of genes involved in inflammation as well as growth and development, 
and is also a target of curcumin. Egr-1 regulates several pathophysiologically relevant genes in 
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the vasculature that are involved in differentiation, wound healing and blood clotting (194).  It 
has been shown that curcumin suppressed the induction of Egr-1 in endothelial cells and 
fibroblasts, thereby modulating the expression of Egr-1-regulated genes in both these cell types 
(195). A recent study also showed that curcumin inhibits the inflammatory response and 
chemotaxis of monocytes by inhibiting Egr-1 (196). 
Curcumin also downregulates MAPK pathways, which are activated by many 
inflammatory stimuli (194). Curcumin can contribute to the protection against the adverse 
vascular effect of the pro-inflammatory response through the suppression of TNF-α-stimulated 
ROS generation, monocyte adhesion, phosphorylation of JNK and p38 MAPK, and signal 
transducer and activator of transcription (STAT)-3 in endothelial cells (197). In vitro studies are 
somewhat contradictory since other investigators paradoxically show an activation of MAPK by 
curcumin (198, 199). The mechanism is unexplained, nevertheless; in both cases its final effects 
appear to be anti-inflammatory (172).  
Curcumin thus exerts a protective role against inflammatory responses, through 
modulation of inflammatory mediators, and may therefore represent a therapeutic agent targeting 
the cardiovascular system since the inflammatory process plays a crucial role in the pathogenesis 
of some cardiovascular diseases, mainly atherosclerosis and acute coronary syndrome (200). 
1.16.2 Antioxidant activity of curcumin  
The antioxidant activity of curcumin was reported as early as 1975 (201). Oxidative stress 
associated with overproduction of ROS plays a major role in the pathogenesis of various 
diseases, including CVDs (158). Even though the antioxidant properties of curcumin have been 
shown to have several therapeutic advantages, its antioxidant mechanism remains poorly 
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understood. It has been shown to be a potent scavenger of a variety of ROS, including O2˙- (174), 
OH- (202), nitrogen dioxide radicals (203) and non-free radical species such as H2O2 (174). 
Curcumin has also been shown to enhance the activity of antioxidant enzymes and to counteract 
the activity of ROS generating enzymes (170, 204). Sreejayan and Rao first claimed that the 
presence of phenolic groups in the structure of curcumin was fundamental in its ability to 
eliminate ROS (205). Recent literature proposes that the phenolic and methoxy groups on the 
phenyl ring and the 1,3-diketone system are important structural features that contribute to the 
antioxidant effects. Evermore so, the antioxidant activity increases when the phenolic group with 
a methoxy group is at the ortho position (206). A more recent study concluded that the H-atom 
donation from the phenolic group is responsible for the strong antioxidant properties of curcumin 
(174). Curcumin can also indirectly increase the endogenous cellular antioxidant defenses 
through alternative antioxidant mechanisms. Heme-oxygenase-1 (HO-1) is a widely distributed 
mammalian enzyme that is one of the most prominent protective genes proven to be effective in 
ameliorating cardiovascular problems associated with increased oxidative stress (158), and is yet 
another target of curcumin (207). Curcumin has been shown to protect against oxidative stress 
through an increase in HO-1 production in endothelial cells (206). 
Curcumin has the ability to protect lipids and DNA against oxidative degradation by 
scavenging free radicals and inhibiting free radical generation (203, 208, 209). Lipids are the 
most susceptible macromolecules to oxidative stress (203) and lipid peroxidation consists of a 
series of free radical-mediated chain reaction processes that leads to the damage of cell 
membranes. Many studies demonstrate the potential of curcumin to reduce lipid peroxidation, a 
key process in the onset and progression of many diseases, including atherosclerosis, heart 
diseases and cancer (210-213). Curcumin has been shown to reduce lipid peroxidation by 
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augmenting the activities of antioxidant enzymes, such as superoxide dismutase (SOD), catalase, 
glutathione (GSH), glutathione-s-transferase (GST) and glutathione peroxidase (GPx) (170). 
Curcumin also exhibits a protective role against oxidative ischemic injury through 
inhibition of free radical propagation with subsequent inhibition of ROS generating enzyme 
activity, resulting in decreased ROS production (214). 
Although the exact mechanism by which curcumin promotes these effects remains to be 
elucidated, in vivo and in vitro studies suggest that its antioxidant properties appear to underlie its 
pleiotropic biological activities. 
1.16.3 Anticarcinogenic effects of curcumin  
In vivo and in vitro studies have demonstrated the ability of curcumin to inhibit 
carcinogenesis at three stages: tumour initiation, promotion and metastasis (215). Its anti-
carcinogenic effect has been studied in gastrointestinal, liver, lung, blood, breast, oral, prostate 
and skin cancers. The molecular basis of the anti-carcinogenic and chemopreventive effects of 
curcumin is attributed to its effect on several targets including transcription factors, growth 
regulators, apoptotic genes, angiogenesis regulators and cellular signaling molecules (215). 
Cancer cells are able to evade apoptosis and grow in a rapid and uncontrolled manner. Curcumin 
has been shown to suppress the proliferation of tumor cells through the activation of caspases, the 
induction of tumor suppressor genes, such as p53, the upregulation of proapoptotic proteins and 
the downregulation of anti-apoptosis proteins (216, 217). Curcumin has been shown to induce in 
vitro and in vivo apoptosis of various tumour cell lines such as breast cancer cells, lung cancer 
cells, human melanoma cells, human myeloma cells, human leukemia cells, human 
neuroblastoma cells, oral cancer cells and prostate cancer cells (reviewed in (215)). Besides 
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inducing apoptosis, curcumin also inhibits the expression of PI3-K and the phosphorylation of the 
pro-survival kinase Akt/PKB (217).  
Curcumin has also been shown to suppress growth factor-induced actions on human 
cancer cell growth. Recent in vitro studies have shown that treatment of cancer cells with 
curcumin can inhibit the intrinsic EGF-R tyrosine kinase activity, EGF-R ligand-induced 
activation, as well as the expression of EGF-R (218). Curcumin has been shown to inhibit human 
colon cancer cell growth by suppressing gene expression of EGF-R through reducing the activity 
of transcription factor Egr-1 (219). Recent data further demonstrate that curcumin also inhibits 
the expression and activation of the IGF-1R tyrosine kinase, thereby reversing the IGF-1-induced 
cell growth and apoptosis resistance (220). Moreover, curcumin inhibits PDGF-R-induced 
proliferation and PDGF-induced ERK1/2 phosphorylation of pancreatic stellate cells, through the 
induction of HO-1 gene expression (221). Additional growth factor pathways modulated by 
curcumin include TGF-β, fibroblast growth factor (FGF), hypoxia-inducible factor (HIF)-1α, and 
colony-stimulating factors (CSFs) (reviewed in (175)). 
MAPK signaling is a major pathway used by growth factors to trigger cell proliferation 
and differentiation. In tumor cells, curcumin, through inhibition of JNK phosphorylation, was 
shown to effectively block AP-1 and NF-κB signaling pathways (222). Furthermore, curcumin 
strongly repressed tumor promoter-induced phosphorylation of ERK, JNK and p38 MAPK in 
brain tumor cells (223).  Curcumin inhibition of gene expression of Egr-1 also requires 
interruption of ERK MAPK signal pathway (219). Several ongoing clinical trials still remain 
inconclusive, yet curcumin appears to have therapeutic potential for both prevention and 
treatment of cancer. Pharmacologically, it is safe in humans but its limited bioavailability 
interferes with its therapeutic potential. 
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1.17 Curcumin and cardiovascular diseases 
Most of the earlier studies on curcumin focussed on its beneficial effects in various 
models of cancer, however, its anti-inflammatory and antioxidant properties have generated 
interest to investigate if this compound can also exert cardiovascular protective effects. Even 
though the underlying mechanism of action is not fully understood, evidence that curcumin exerts 
protective effects on the cardiovascular system has been previously described and its use as a 
therapeutic agent to mitigate CVDs is currently being investigated. Evidence indicates that 
curcumin exhibits protective effects against cardiovascular pathologies such as atherosclerosis, 
cardiac hypertrophy and heart failure. 
1.17.1 Curcumin and atherosclerosis 
Atherosclerosis is the most common form of heart disease.  It is considered a chronic and 
progressive disease arising from the inflammatory processes and oxidative stress within the 
vessel wall (224). Curcumin has been shown to exhibit anti-atherosclerotic action through 
inhibition of platelet aggregation (225), protection against inflammation and oxidation, and 
modulation of cholesterol homeostasis. Several lines of evidence strongly suggest that curcumin 
may prevent atherosclerosis by regulating some elements in cholesterol homeostasis. Studies 
have reported that curcumin is beneficial in lowering low-density lipoprotein-cholesterol (LDL) 
and raising high-density lipoprotein-cholesterol (HDL) while reducing lipid peroxidation. Animal 
studies conducted in experimental atherosclerotic rabbits reported that curcumin effectively 
inhibited LDL oxidation, and decreased cholesterol and triglycerides levels (211). 
Supplementation with curcumin also demonstrated a significant prevention of early 
atherosclerotic lesions in thoracic and abdominal aorta, through reduction in oxidative stress and 
decreased lipid peroxidation, resulting in reduction of aortic fatty streak formation, in 
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experimental model of atherosclerosis where rabbits were fed a high cholesterol diet for 30 days 
(226). Orally administered curcumin also decreased the formation of atherosclerotic lesions by 
20% in apoE and LDL receptor-double knockout mice model, an animal model developed for 
experimental atherosclerotic research (227). In a recent study, Liao et al. demonstrated that 
curcumin induced a 50% reduction in atherosclerotic lesion reduction in apoE knockout mice and 
inhibited oxidized-LDL-induced cholesterol accumulation in cultured VSMC (228). Curcumin 
has also proven to be an effective antioxidant through the prevention of oxidation and 
modification of LDL, and the subsequent restoration of prostacyclin release in human endothelial 
cells, thereby indicating a protective role in preventing pathological conditions related to 
oxidative stress and the development of atherosclerosis (229). 
In humans, a study involving the administration of 500 mg of curcumin for 7 days to 10 
healthy volunteers revealed a 29% increase in HDL cholesterol, a 12% decrease in total serum 
cholesterol and a 33% decrease in serum lipid peroxidases (230). The administration of curcumin 
also reduced total and LDL cholesterol levels in patients with acute coronary syndrome (231). 
Another study showed that 10 mg of curcumin given twice daily during 30 days significantly 
lowered the serum LDL levels and increased the serum HDL levels in healthy patients (232). The 
same group reported that 10 mg of curcumin administered twice daily for 15 days significantly 
lowered plasma fibrinogen levels in humans with atherosclerosis (233).  
Abnormal proliferation of VSMC and mononuclear cells also contributes to the 
progression of cardiovascular diseases, including atherosclerosis. Curcumin suppressed mitogen-
induced proliferation of human blood mononuclear cells, inhibited neutrophil activation and 
mixed neutrophil reaction, and also inhibited serum-induced as well as PDGF-dependent 
proliferation of rabbit VSMC (234). VSMC migration and collagen synthesis are also key events 
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involved in the pathological changes occurring with atherosclerosis. Curcumin has potent 
inhibitory effects on PDGF-induced VSMC proliferation, migration and collagen synthesis (235). 
This inhibitory effect on vascular remodeling is attributable to the attenuation by curcumin of 
PDGF-induced PDGF-R, ERK1/2 and Akt signaling in VSMC (235). Using an animal arterial 
balloon-injury model characterized by PDGF-R upregulation to substantiate the in vitro results, 
curcumin significantly inhibited neointima formation, collagen synthesis, cell proliferation and 
the overexpression of PDGF-R (235). Curcumin also decreased cholesterol-induced proliferation 
of aortic rat VSMC and suppressed the phosphorylation of ERK1/2 as well as its translocation to 
the nucleus (236). The vascular anti-proliferative effect of curcumin has also been demonstrated 
through the induction of HO-1 expression in rat and human VSMC (237). Curcumins potential 
role in the prevention of atherosclerosis is further supported through its inhibitory effect on 
VSMC migration (238). This inhibitory effect was observed on TNF-α-induced migration that 
was mediated by decreasing TNF-α-induced ROS production, leading to suppression of matrix 
metallopeptidase 9 (MMP-9) activation and protein expression through the downregulation of 
NF-κB (238). Synthetic curcuminoids have also been shown to exert anti-proliferative effects on 
cell growth. Dehydrozingerone, a biosynthetic structural analogue of curcumin, inhibited PDGF-
stimulated VSMC migration, proliferation, collagen synthesis, and PDGF/H2O2-stimulated 
phosphorylation of PDGF-R and downstream Akt (239). HO-3867, another synthetic 
curcuminoid, significantly inhibited the proliferation of serum-stimulated VSMC (240). 
Hydrazinocurcumin, yet another synthetic curcumin derivative, potently inhibited the 
proliferation of bovine aortic endothelial cells (241). These studies support the notion that 
curcumin confers protection against pathological remodeling of blood vessels, a contributory 
mechanism of atherosclerosis.  
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Since atherosclerosis is a chronic inflammatory disease associated with increased 
oxidative stress in VSMC, it would be possible that the anti-atherogenic effects of curcumin are 
attributable to its antoxidant and anti-inflammatory properties (238). Curcumin modulates several 
targets that mediate an anti-atherosclerotic effect but the detailed anti-atherosclerotic mechanisms 
of curcumin still remain to be elucidated. 
1.17.2 Curcumin effects on the heart 
The effect of curcumin on cardiac hypertrophy and myocardial ischemia (MI) has been 
studied in both in vivo and in vitro models. Cardiac hypertrophy is an adaptive enlargement of the 
myocardium in response to a variety of stresses, such as an increased workload or myocardial 
infarction, and is characterized by an increase in the size of the individual cardiomyocytes and 
the whole heart (242). Cardiac remodeling plays a critical role in the progression of pathologic 
cardiac hypertrophy to heart failure and death (242). Hypertrophic stimuli initiate several 
subcellular signaling pathways and these signals reach the nuclei of cardiomyocytes and activate 
a subset of hypertrophy-responsive transcription factors that change the pattern of the gene 
expression. Activation of these transcription factors is mediated, in part, through post-
transcriptional modifications, such as acetylation by histone deacetylases and an intrinsic histone 
acetyltransferase (HAT), p300 (243). Nuclear acetylation by p300 is a critical event during cell 
hypertrophy. Activation of p300 is not only required for pathological myocyte growth but also 
for normal myocardial development and differentiation. p300 also induces the expression of 
genes encoding atrial natriuretic factor (ANF), ET-1, and β-myosin heavy chain (β-MHC), which 
are well established markers of myocardial cell hypertrophy (244-246). Curcumin was reported to 
be an inhibitor of p300-HAT and was found to repress the p300 induced hypertrophic responses 
in cultured neonatal cardiomyocytes, including the expression of both ANF and β-MHC genes 
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(247). It also inhibited the p300 HAT activity and thereby prevented the development of heart 
failure in two different heart failure models in vivo, a hypertensive heart disease in salt-sensitive 
Dahl rats and in a surgically-induced myocardial infarction in rats (247). 
Heart failure is a process of systemic inflammation with overexpression of local 
inflammatory cytokines including TNF-α (248). Recent reports have shown that TNF-α 
contributes to the process of myocardial remodeling in evolving heart failure (249). Orally 
administered curcumin improved left ventricular function in rabbits exhibiting heart failure-
induced by pressure overload that resulted from the inhibition of myocardial collagen remodeling 
associated with suppression of TNF-α expression (250).  
As previously mentioned, curcumin also behaves as a free radical scavenger and 
antioxidant, inhibiting lipid peroxidation and oxidative DNA damage. Puvanakrishnan et al. 
reported that curcumin plays a protective role against isoproterenol-induced myocardial necrosis 
in rats and that this protective effect is attributed to its antioxidant properties (214). L-
Isoproterenol (ISO) is a synthetic cathecholamine that causes myocardial damage when 
administered in large doses. Orally administered curcumin (200mg/kg) protected against ISO-
induced oxidative myocardial injury in rats through enhancement of the antioxidant defense and 
thereby exhibited cardioprotective activity against ISO-induced cardiotoxicity (251). 
Furthermore, Venkatesan observed a protective effect of orally administered curcumin against 
cardiotoxicity produced by adriamycin in rats, showing a reduction in the parameters that indicate 
lipid peroxidation (252). Moreover, curcumin suppressed neutrophil infiltration into the human 
injured myocardium (164). Neutrophils are a major source of free radicals that characteristically 
invade the myocardial tissue during ischemia (164). 
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Ang II can play a critical role in the genesis of cardiac hypertrophy in hypertension and 
MI (253). Cardiac hypertrophy in response to Ang II is initiated though activation of its 
receptors, which results in marked oxidant stress via NADPH oxidase and NF-κB activation 
(254, 255). Downstream of NADPH oxidase lies the major redox-sensitive transcription factor 
NF-κB, which is perhaps the most critical transcription factor in mediating the transcription of a 
host of pro-inflammatory, pro-oxidant, and pro-growth genes, in response to Ang II (256).  
Freund et al. demonstrated the requirement of NF-κB in Ang II-mediated cardiac hypertrophy in 
vivo (257). Curcumin attenuates Ang II-mediated ROS generation, and the expression of NADPH 
oxidase and NF-κB in cardiomyocytes (253). Attenuation of the redox state by curcumin results 
in the abrogation of Ang II-mediated cardiomyocyte growth as well as the expression of the 
hypertrophic markers, ANP and BNP. Oxidized-LDL receptor-1 (LOX-1) upregulation has a 
central role in cardiomyocyte hypertrophy response to Ang II (253). Curcumin reduced the Ang 
II-mediated upregulation of Ang II type 1 receptor (AT1R) and LOX-1 expression and activation 
which translates into a strong inhibition of redox signaling resulting in a marked inhibition of 
cardiomyocyte growth (253).    
1.17.3 Curcumin and hypertension 
 The effect of curcumin on hypertension has not been explored in detail, yet a recent study 
revealed for the first time, under in vivo conditions, that curcumin attenuated the development of 
hypertension in NO-deficient hypertensive rats (163). Curcumin suppressed blood pressure 
elevation, decreased vascular resistance and restored vascular responsiveness in rats with Nω-
nitro-L-arginine methyl ester (L-NAME)-induced hypertension, through an antioxidant 
mechanism (163). Curcumin has also been shown to induce vasorelaxation on isolated porcine 
coronary arteries through its antioxidant capacity to promote NO release (258). Moreover, 
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curcumin supplementation showed significant attenuation of mean arterial blood pressure in 
streptozotocin-induced diabetic rats (259). In humans, oral turmeric supplementation decreased 
systolic blood pressure in patients with kidney disease, lupus nephritis (260). Curcumin 
supplementation may therefore be beneficial in improving vascular function and preventing 
cardiovascular complications. 
1.17.4 Curcumin and diabetic cardiovascular complications  
A pilot study done in 1972 reported that curcumin lowered blood sugar levels in human 
diabetic subjects (261). Since then, the modulation of curcumin has been extended to elucidate 
the molecular basis for obesity and obesity-related metabolic diseases, including type 2 diabetes 
and cardiovascular diseases. The anti-diabetic effects of curcumin are also linked with the 
inhibition of inflammatory and oxidative markers. Increased oxidative stress has been associated 
with the pathogenesis of chronic diabetic complications, including cardiomyopathy (262). It has 
been suggested that NO pathway is involved in augmenting oxidative stress (263). Many studies 
have shown the implication of eNOS and iNOS in the pathogenesis of cardiovascular 
complications in diabetes (264). In a study where myocardial tissue from diabetic rats exhibited 
increased levels of eNOS and iNOS mRNA, curcumin treatment prevented this NOS mRNA 
upregulation leading to a decrease in the oxidative DNA damage in association with a reduction 
in the expression of transcription factors NF-κB and AP-1 (265).  
 Diabetic cardiomyopathy eventually leads to heart failure (186). Transcriptional co-
activator p300 and its interaction with myocyte enhancer factor 2 (MEF2) play a role in diabetes-
induced cardiomyocyte hypertrophy. Curcumin treatment prevented diabetes-induced 
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upregulation of these transcripts, suggesting a protective mechanism in glucose-induced 
cardiomyocyte hypertrophy in diabetes (266).  
NF-κB, TNF-α and Egr-1 have been closely linked with the induction of insulin 
resistance, a key feature in type II diabetes mellitus. Curcumin has been shown to downregulate 
these biomarkers (195, 267-270), suggesting a putative mechanism in overcoming insulin 
resistance as demonstrated by several animal studies (271-273). 
Hyperglycemia leads to increased oxidative stress resulting in endothelial dysfunction. A 
randomized 8 week-study was performed on 72 patients with type II diabetes to evaluate the 
effects of curcumin on endothelial dysfunction in association with reductions in inflammatory 
cytokines and markers of oxidative stress. Patients receiving 150 mg of curcumin twice daily 
showed an improvement of endothelial function and significant reductions in the levels of 
malondialdehyde, ET-1, IL-6, and TNF-α (274). Curcumin supplementation also improved 
diabetes-induced endothelial dysfunction in streptozotocin-induced diabetic rats through 
decreased PKC expression and decreased ROS production (259). 
The precise mechanism by which curcumin improves vascular homeostasis remains 
unclear. However, the ability of curcumin to ameliorate pathophysiological states, such as 
atherosclerosis, cardiac remodeling and myocardial ischemia, through antioxidant and anti-
inflammatory properties, have been suggested to contribute to this response. 
1.18 Goal of this study 
The broad biological activity of curcumin, including antioxidant and anti-inflammatory 
effects, influences key cellular signal transduction pathways in multiple diseases. Curcumin has 
proven to be beneficial in studies within the cardiovascular system involving atherosclerosis, 
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ischemia-induced diseases, diabetic-induced cardiovascular complications, cardiac hypertrophy 
and myocardial infarction. However, very little is known regarding the molecular mechanisms 
involved in mediating these responses.  
ET-1 is a very potent active molecule that plays an important role in health and disease 
through its ability to regulate various cardiovascular functions. ET-1 activates multiple signaling 
pathways including MAPK and PI3-K/PKB which mediate the hypertrophic and proliferative 
responses in VSMC. An important role of oxidative stress generation in mediating the effect of 
ET-1 has been demonstrated. Moreover, ROS are produced and act as second messengers as part 
of the signaling of receptor protein tyrosine kinases, which are activated after vascular injury. 
Curcumin has been shown to suppress ROS generation and to inhibit several of the mediators 
involved in the ET-1 signaling pathway in several cellular lines. Curcumin has also been shown 
to inhibit cell proliferation, arrest cell cycle progression and induced cell apoptosis in VSMC 
(275). However, the effect of curcumin in ET-1-induced signaling in VSMC has not been 
investigated. Therefore, the present study aims at examining the effect of curcumin on ET-1-
induced phosphorylation of ERK1/2, c-Raf, PKB and IGF-1R. Since ET-1 action requires IGF-
1R transactivation we have also investigated if curcumin modulates IGF-1-induced signaling in 
VSMC. In addition, we tested if the transcription factor Egr-1 is also a target of curcumin in 
response to ET-1 as well as IGF-1. 
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Abstract 
Despite recent advances, mortality from cardiovascular disease remains high, highlighting the 
requirement for improved therapies. Several studies have demonstrated a correlation between 
cardiovascular disease and an increased activation of ET-1-induced signaling in vascular smooth 
muscle cell (VSMC), including protein kinase B (PKB) and extracellular  signal-regulated kinase 
1 and 2 (ERK1/2) pathways, as well as an increase in ET-1-mediated VSMC hypertrophy and 
proliferation. Oxidative stress has been suggested to play an intermediary role in mediating ET-1-
induced cardiovascular pathophysiological effects. Curcumin (diferuloylmethane), a major 
component of the spice turmeric, has been shown to exhibit cardiovascular protective effects 
mainly through its antioxidant and anti-inflammatory properties. The current study was 
undertaken to examine the effectiveness of curcumin to inhibit ET-1-stimulated signaling events 
in A-10 VMSC. ET-1 (100nM) produced a marked phosphorylation of PKB, ERK1/2, c-Raf and 
insulin-like growth factor type 1 receptor (IGF-1R), in VSMC, that was dose dependently 
inhibited by pretreatment with curcumin. Curcumin also attenuated IGF-1-induced 
phosphorylation of PKB, ERK1/2 and c-Raf as well as phosphorylation of IGF-1R. Furthermore, 
curcumin also inhibited ET-1 and IGF-1-induced expression of early growth response-1 (Egr-1), 
a transcription factor downstream of ERK1/2 that plays a regulatory role in several 
cardiovascular pathological processes. In conclusion, these data provide evidence that curcumin 
is a potent inhibitor of ET-1 and IGF-1-induced mitogenic and proliferative signaling responses 
in A-10 VSMC and suggest that the ability of curcumin to attenuate these events may contribute 
as a potential mechanism for its cardiovascular protective effects. 
 
Key words: Curcumin, Early growth response-1, Endothelin-1, Extracellular signal-regulated 
kinase 1 and 2, Insulin-like growth factor type 1, Insulin-like growth factor type 1 receptor, 
Protein kinase B, Vascular smooth muscle cells 
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Introduction 
Endothelin-1 (ET-1) is a potent vasoconstrictor peptide that has been shown to exhibit mitogenic 
and hypertrophic responses in vascular smooth muscle cells (VSMC) (1, 2). A potential role of 
ET-1 in promoting the pathophysiology of cardiovascular diseases such as coronary artery 
disease (3), hypertension (4), heart failure (4) and vascular remodeling (atherosclerosis and 
restenosis) (5) has been suggested. VSMC play a critical role in the structural and functional 
characteristics of the vessel wall, including growth, repair and remodeling (6). ET-1 mediates its 
effects on VSMC through interaction with its two subtypes of heterotrimeric G protein coupled 
receptors (GPCR), ETA and ETB (1, 2). This leads to the activation of multiple signaling 
pathways, including growth promoting mitogen-activated protein kinases (MAPK), of which 
extracellular signal-regulated kinase 1 and 2 (ERK1/2) is the most well characterized, and 
phosphatidylinositol 3-kinase (PI3-K)/protein kinase B (PKB) pathways (1, 2). An intermediary 
role of transactivation of growth factor receptor protein tyrosine kinases (R-PTK) in transducing 
ET-1-induced signaling events has been proposed (7). In this regard, we have recently shown that 
insulin-like growth factor type 1 receptor (IGF-1R) plays a critical role in mediating ET-1-
induced PKB activation, as well as hypertrophic and proliferative responses induced by ET-1 in 
VSMC (7). Although the mechanism of action responsible for R-PTK transactivation is not yet 
fully understood, several factors are suggested to be implicated in this process. Amongst them, 
the generation of reactive oxygen species (ROS) which has been shown to play an important role 
in inducing the activation of ERK1/2 and PKB signaling in VSMC in response to ET-1 (8), has 
also been shown to contribute to the activation of IGF-1R-PTK in VSMC (9). IGF-1R is 
classically activated by its growth factor ligand, insulin-like growth factor type 1 (IGF-1). IGF-1 
can be synthesized and secreted in cultured VSMC (10), and has been shown to act as a potent 
mitogen for VSMC in vitro (11, 12). ERK1/2 and PI3-K/PKB signaling promotes IGF-1-induced 
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mitogenic and proliferative responses respectively, in VSMC (13, 14).  Accordingly, inhibition of 
ET-1 and IGF-1-stimulated VSMC signaling pathways may serve as a potential therapeutic 
intervention to attenuate cellular manifestations associated with the progression of many vascular 
diseases. 
Curcumin, a natural polyphenolic compound found in the spice turmeric (Curcuma 
Longa), has recently attracted much attention as it has been shown to exhibit a vast array of 
biological activities, including antioxidant, anti-proliferative, anti-tumour and anti-inflammatory 
properties (15). Several studies have suggested that curcumin may play a role in the protection 
against certain cardiovascular diseases, including arterial disease (16), atherosclerosis (17), 
cardiac hypertrophy (18-20), heart failure (20), and damage caused by myocardial ischemia (21-
23). The precise mechanisms responsible for the cardiovascular protective effect remains obscure 
however, curcumin has been shown to exert its effects on several signaling pathways linked to 
growth, proliferation and gene expression (24-29). It has been shown to inhibit serum-induced 
and platelet-derived growth factor (PDGF)-dependent mitogenesis in VSMC (26). In a recent 
study, curcumin attenuated PDGF-induced signaling in VSMC through inhibition of PDGF 
receptor, ERK1/2 and PKB phosphorylation (25). Since curcumin exhibits anti-proliferative 
effects and has potent antioxidant properties with its ability to scavenge ROS (30-32), and ET-1 
exerts its effects through the generation of ROS with an intermediary role of IGF-1R 
transactivation (7, 8), the purpose of this study was to investigate the effect of curcumin on ET-1 
and IGF-1-mediated proliferative and hypertrophic signaling responses in VSMC. Therefore, we 
examined the effect of curcumin on ET-1 and IGF-1-induced phosphorylation of IGF-1R, c-Raf, 
ERK1/2 and PKB, key mediators involved in growth-promoting, proliferative and hypertrophic 
responses. In addition, we have also investigated the effect of curcumin on early growth response 
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(Egr)-1, a transcription factor which is a downstream target of ERK1/2 and is implicated in 
multiple cardiovascular pathological processes (33). 
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Materials and Methods 
 
Antibodies and reagents:  
Cell culture reagents were procured from Invitrogen Corp. (Grand Island, NY). ET-1 was 
purchased from American Peptide Inc. (USA). IGF-1 was purchased from Peprotech Inc. (USA). 
Monoclonal phospho-specific-Tyr204 ERK1/2, polyclonal ERK1/2, anti-IGF-1R, Egr-1 and 
GAPDH antibodies, as well as horseradish peroxidase-conjugated goat anti-mouse 
immunoglobulin were from Santa Cruz Biotech (Santa Cruz, CA). The phospho-Ser473-specific-
PKB, anti-PKB, phospho-Ser338-specific-c-Raf, anti-c-Raf and anti-rabbit antibodies were from 
Cell Signaling (Beverly, MA). Curcumin was procured from Calbiochem (San Diego, CA). Anti-
phosphospecific IGF-1R (phospho-Tyr1158/1162/1163) antibody was obtained from Biosource. 
Hoechst 33342 (10mg/ml) was obtained from Invitrogen. The enhanced chemiluminescence 
(ECL) detection kit was from Amersham Pharmacia Biotech (Baie d’Urfé, Qc, Canada).  
 
Cell culture: 
VSMC are derived from embryonic rat thoracic aorta A-10 cells and were maintained in culture 
with Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) 
and 1% penicillin + streptomycin, at 37oC in a humidified atmosphere of 5% CO2. Cells were 
grown to 80-90% confluence in 60mm plates and incubated in serum-free DMEM 20 hours prior 
to treatment. They were passaged twice a week by harvesting with Trypsin/EDTA. 
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Immunoblotting: 
Cells incubated in the absence or presence of various agents were washed twice with ice-cold 
PBS and lysed in 200μl of buffer (25nM Tris-HCl, pH 7.5. 25mM NaCl, 1mM Na orthovanadate, 
10mM Na fluoride, 10 mM Na pyrophosphate, 2 mM benzamidine, 2 mM ethylenebis 
(oxyethylenenitrilo)-tetraacetic acid (EGTA), 2mM ethylenediamine-tetraacetic acid (EDTA), 1 
mM phenylmethylsulphonyl fluoride (PMSF), 10 μg/ml aprotinin, 1% Triton X-100, 0.1% 
sodium dodecyl sulfate (SDS) and 0.5 μg/ml leuleptin) on ice. The cells were scraped, collected 
and clarified by centrifugation at 12,000g for 10 minutes at 4oC to remove insoluble materials. 
Protein concentrations were measured using Bradford assay. Equal amounts of protein were 
subjected to 7.5% SDS-polyacrylamide gel (SDS-PAGE), transferred to polyvinylidine difluoride 
(PVDF) membranes (Millipore, MA, USA). The membranes were blocked 1 hour with PBS-
Tween 20 containing 5% non-fat dry milk at room temperature and then incubated overnight at 
4oC with respective primary antibodies (Monoclonal phospho-specific-Tyr204 ERK1/2 antibody 
(1:4000), phospho-Ser338-specific-c-Raf (1:2000), phospho-Ser473-specific-PKB antibody 
(1:2000), phosphor-Tyr1131/1135/1136-specific-IGF-1R (1:000), Egr-1 (1:1000), anti-PKB (1:2000), 
polyclonal ERK1/2 (1:4000), anti-c-Raf (1:2000), anti-IGF-1R (1:1000) and GAPDH (1:2000)). 
The antigen-antibody complex was detected by horseradish peroxidase-conjugated second 
antibody (1:4000), and protein bands were visualized by ECL. The intensity of the bands was 
quantified by densitometric analysis using Quantity One imaging and Graphpad Prism 5 software 
programs.  
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Nuclear extraction protocol 
Cells incubated in the absence or presence of various agents were washed twice with ice-cold 
PBS and collected in 500μl of buffer solution containing 10mM Hepes, 10mM KCl, 0.1mM 
EDTA, 0.1mM EGTA, 1mM PMSF, 1mM protease cocktail inhibitor and 1mM Na 
orthovanadate. Lysates were incubated in ice for 15 minutes before the addition of NP40 10% 
detergent and then they were vortexed for 10 seconds at highest setting before being centrifuged 
at 13000RPM for 4 minutes at 4oC. The supernatant (that corresponds to the cytoplasmic 
fraction) was saved and transferred in a clean tube. The pellet was resuspended in 60μl, by 
pipeting up and down several times, in buffer containing 10mM Hepes, 400mM NaCl, 0.1mM 
EDTA, 0.1mM EGTA, 1mM PMSF, 1mM protease cocktail inhibitor and 1mM Na 
orthovanadate. Lysates were sonicated by performing 6 cycles at 10 seconds per cycle with 30 
second intervals and then centrifuged at 13000RPM for 5 minutes at 4oC. Pellet was discarded 
and the supernatant, which corresponds to the nuclear fraction, was collected. Protein 
concentrations were measured using Bradford assay. 
 
Apoptosis assay 
Curcumin-induced apoptosis was monitored by the extent of nuclear fragmentation. Nuclear 
fragmentation was visualized by Hoechst 33342 staining of apoptotic nuclei. Hoeckst 33342 is a 
fluorescent bisbenzimide that stains DNA and penetrates membranes of dead cells. It is excited 
by ultraviolet light of 350nm and emits blue light of 461nm wavelength. After treatment with 
varying concentrations of curcumin for 30 minutes cells were treated with 2% paraformaldehyde 
(diluted in PBS) in 2000µL basal medium. The adhered cells were then stained with 2.5µL of 
Hoechst 33342 (10mg/ml Invitrogen) in 2500µL medium and incubated at room temperature in 
the dark for 15 minutes. The cells were imaged under an Olympus BH-2 fluorescence microscope 
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using 350nm stimulation and 460nm emission. Triplicates samples were used for each treatment. 
Under our assay the treatment of A-10 VSMC for 30 minutes at 50 µM did not cause any 
significant cell death (data not shown). 
 
Statistics: 
Statistical analysis was performed by one-way, repeated-measures analysis of variance 
(ANOVA) followed by a Tukey post hoc test. All data are reported as means + SE. the 
differences between means were considered significant at P<0.05. 
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Results 
Curcumin inhibits ET-1- and IGF-1-induced phosphorylation of PKB in A-10 VSMC 
 
PKB activation has been shown to contribute to hypertrophic responses in VSMC 
(reviewed in (1)). Therefore, we investigated the effect of curcumin on PKB phosphorylation 
induced by ET-1 and IGF-1. As shown in Fig. 1 both ET-1 and IGF-1 enhanced the 
phosphorylation of PKB 3 fold and 15 fold, respectively. However, pretreatment of A-10 VSMC 
with curcumin for 30 minutes dose-dependently attenuated both ET-1 and IGF-1-induced 
phosphorylation of PKB. The attenuating effect of curcumin could be detected at 5µM but was 
more prominent at higher concentrations and at 25µM almost complete inhibition of ET-1-
induced PKB phosphorylation was observed (Fig. 1A). Similarly, curcumin also inhibited IGF-1-
induced phosphorylation of PKB in these cells but appeared to be slightly less potent as 
compared to its effect on ET-1-induced response (Fig. 1B).  
 
Curcumin inhibits ET-1- and IGF-1-induced phosphorylation of c-Raf and ERK1/2 in A-10 
VSMC 
 
Activation of ERK1/2 signaling has been implicated in mediating hypertrophic and 
proliferative effects of ET-1 (34, 35). Therefore, we next investigated the effect of curcumin on 
ERK1/2 signaling (Fig 2). Treatment with ET-1 and IGF-1 increased ERK1/2 phosphorylation in 
A-10 VSMC (Fig. 2). However, pre-treatment of the cells with curcumin prior to stimulation with 
either ET-1 or IGF-1 resulted in a significant inhibition in ERK1/2 phosphorylation induced by 
both ET-1 and IGF-1 (Fig. 2). Curcumin had no effect on the expression of ERK1/2 protein (Fig. 
2). 
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ERK1/2 activation requires sequential activation of Ras, Raf and MEK upstream signaling 
components (1). Therefore, we examined the effect of curcumin on the activated c-Raf levels by 
measuring the phosphorylation level of the c-Raf protein at serine 338 in A-10 VSMC treated 
with ET-1 and IGF-1. As shown in Fig. 3, curcumin pretreatment markedly inhibited the 
phosphorylation of c-Raf stimulated by both agents in a dose-dependent manner without altering 
the levels of this protein. The inhibitory effect of curcumin on both ET-1 and IGF-1-induced 
phosphorylation of c-Raf was quite significant at 25µM and became even more prominent at 50 
µM, where almost complete inhibition was observed (Fig. 3). These data indicate that curcumin 
inhibits the phosphorylation and hence the c-Raf kinase activity of this upstream component of 
ERK1/2 signaling pathway and thereby inhibits ET-1 and IGF-1-induced phosphorylation of 
ERK1/2 in A-10 VSMC.  
 
Attenuation of ET-1- and IGF-1-induced tyrosine phosphorylation of IGF-1R β subunit by 
curcumin in A10-VSMC 
 
 Since, we have previously reported that ET-1 is capable of increasing tyrosine 
phosphorylation of IGF-1R β subunit, which is required for its activation, and that IGF-1R-PTK 
is involved in mediating ET-1-induced PKB activation in A-10 VSMC (7), we next tested the 
effect of curcumin on the ET-1-mediated phosphorylation of IGF-1R. As shown in Fig. 4A, when 
compared with ET-1 alone, curcumin inhibited ET-1-induced phosphorylation of IGF-1R. A 
pronounced attenuating effect was detected at 5µM whereas almost complete inhibition of IGF-
1R phosphorylation was observed at 25µM (Fig. 4A).  In order to distinguish this ET-1-induced 
transactivation of IGF-1R with the ligand-dependent activation of IGF-1R, we investigated the 
effect of curcumin on IGF-1-induced phosphorylation of IGF-1R. As expected, IGF-1 increased 
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IGF-1R phosphorylation and curcumin dose-dependently attenuated this effect with a marked 
attenuation observed at 25µM and an almost complete inhibition observed at 50µM (Fig. 4B).  
 
Inhibition of ET-1- and IGF-1-induced upregulation of Egr-1 by curcumin in A-10 VSMC 
 It has been suggested that Egr-1 plays a regulatory role in multiple cardiovascular 
pathological processes (33). It has a low basal level expression in normal vessels but is rapidly 
and transiently expressed in VSMC and endothelial cells in response to injury (36). Egr-1 protein 
is biologically active and has exerts profound chemotactic and mitogenic effects in injured 
vascular cells, which may contribute to the structural remodeling that typically occurs in the 
pathogenesis of vascular diseases (36). Therefore, we wished to determine if ET-1 or IGF-1 will 
upregulate Egr-1 expression in A-10 VSMC. We observed that Egr-1 protein expression was 
upregulated within 30 minutes and peaked at 60 minutes of ET-1 and IGF-1 exposure of A-10 
VSMC (Fig. 5). Since Egr-1 gene expression has been shown to be dependent on ERK1/2 
signaling (33), and curcumin exerts an inhibitory effect on the ERK1/2 pathway, we were further 
interested in investigating the effect of curcumin on ET-1 and IGF-1-induced Egr-1 expression in 
A-10 VSMC. As shown in Fig. 6, pre-treatment of VSMC with curcumin prior to stimulation 
with either ET-1 or IGF-1 inhibited the expression of Egr-1 induced by these two vasoactive 
agents. 
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Discussion 
Curcumin has been suggested to exert cardiovascular protective effects in a variety of 
experimental models. However, the precise molecular mechanism responsible for this response 
remains poorly understood. ET-1 and IGF-1 are important vasoactive peptides with a key role in 
the pathogenesis of vascular disease. The current study has assessed the effect of curcumin, the 
major active ingredient of turmeric (Curcuma Longa) spice, on ET-1 and IGF-1-induced 
signaling events. Here, we demonstrate that curcumin treatment attenuated ET-1 and IGF-1-
induced phosphorylation of IGF-1R, ERK1/2, c-Raf and PKB in VSMC. We also show that 
curcumin treatment also inhibited the expression of zinc finger transcription factor Egr-1 by these 
vasoactive agents.  
There is growing evidence that curcumin has a potential role in the protection against 
cardiovascular diseases. It was reported that curcumin improved the development of cardiac 
hypertrophy, through deactivation of hypertrophic signaling, and heart failure in animal models 
(18, 20). A recent study demonstrated that curcumin attenuated the development of hypertension, 
improved hemodynamic status and restored vascular function in nitric oxide-deficient 
hypertensive rats through alleviation of oxidative stress (37).  
Although, curcumin has been shown to attenuate the response of several growth factors 
and their signaling pathways in cancerous cell lines (24), there are only limited studies on its 
effect in VSMC. Yang et al. have reported an inhibitory effect of curcumin on PDGF signaling 
and PDGF-stimulated VSMC proliferation, migration, and collagen synthesis (25). They 
demonstrated that curcumin inhibits PDGFR phosphorylation as well as the PDGF-induced 
phosphorylation of ERK1/2 and PKB (25). Dehydrozinzerone, a structurally half-analog and 
biosynthetic intermediate of curcumin, also elicited a similar inhibition of PDGF-stimulated 
61 
 
 
phosphorylation of PDGFR, PKB and ERK1/2 in VSMC, leading to the inhibition of VSMC 
migration, proliferation and collagen synthesis (38). However, our work represents the first study 
to demonstrate that curcumin antagonizes both ET-1 and IGF-1-induced IGF-1R 
phosphorylation, as well as their ability to stimulate the phosphorylation of c-Raf, ERK1/2 and 
PKB in VSMC. Given that an upregulated ET-1 system has been linked to hyperproliferation in 
VSMC from SHR (39), it may be suggested that curcumin-induced attenuation of ET-1 signaling 
might serve as one of the mechanisms by which curcumin exerts anti-hypertrophic effects. Since 
curcumin is an antioxidant and ET-1 as well as IGF-1-induced signaling requires ROS generation 
(8, 40), it may be possible that the ability of curcumin to reduces ROS formation may be one of 
the mechanisms by which curcumin exerts its attenuating effect on these signaling events. 
The zinc finger transcription factor Egr-1 plays an important role in vascular biology. The 
Egr family includes Egr-1, Egr-2, Egr-3, and Egr-4. Among the family members, the best 
characterized is Egr-1. Following activation, Egr-1 is primarily expressed in the nucleus and is 
capable of regulating the transcription of several genes implicated in the development of vascular 
disease (41). Egr-1 is weakly, if at all, expressed in normal vessel wall but has been shown to be 
highly expressed in response to acute injury (36, 42) and vasoactive agents, such as angiotensin II 
(Ang II) (43). It is highly expressed in VSMC of atherosclerotic lesions (44) and plays critical 
roles in regulating VSMC growth and intimal thickening after vascular injury (45). ERK1/2 plays 
a prominent role in activating Egr-1 expression in endothelial cells (46) and VSMC (43, 47). 
Studies have shown that attenuation of Egr-1 gene expression inhibits VSMC migration and 
proliferation (48-51). Thus, it may be suggested that curcumin-induced attenuation of Egr-1 
expression may attribute to its cardiovascular protective role. This notion is further supported by 
studies in which antisense nucleotides against Egr-1 were found to block ET-1-induced cardiac 
protein synthesis, a marker of cardiac hypertrophy (52).  
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The antioxidant activity of curcumin was reported as early as 1975 (53). Oxidative stress 
associated with the overproduction of ROS plays a major role in the pathogenesis of various 
cardiovascular diseases, including hypertension and atherosclerosis (54). The antioxidant 
activities of curcumin may be attributable to many factors, including the ability to scavenge ROS, 
the increase in NO bioavailability, and the enhancement of the antioxidant defense system. 
Curcumin has been proven to be a potent scavenger of a variety of ROS including superoxide 
anion radicals (O2-) (30), hydroxyl radicals (OH-) (31), nitrogen dioxide radicals (32) and non-
free radical species such as hydrogen peroxide (H2O2) (30). It has also been shown to enhance the 
activity of antioxidant enzymes (55) and to counteract the activity of ROS generating enzymes 
(56). In human endothelial cells, curcumin was shown to abolish ROS production and attenuate 
NADPH oxidase activity (57). In cardiomyocytes, attenuation of the redox state by curcumin 
resulted in the abrogation of Ang II-mediated cardiomyocyte growth (19). In synergy with its 
anti-inflammatory properties, curcumin prevented VSMC migration through its ability to 
suppress ROS generation (58). Moreover, curcumin has been shown to inhibit H2O2-stimulated 
phosphorylation of PDGF receptor in VSMC (38). As previously mentioned, ET-1 has been 
shown to increase the production of ROS in VSMC and this ROS generation has been shown to 
be a critical mediator in ET-1-induced signaling events linked to growth-promoting proliferative 
and hypertrophic pathways in VSMC (8).  Our earlier studies have also shown that tyrosine 
phosphorylation of β-subunit IGF-1R is an important step in transducing the effect of H2O2 on 
the phosphorylation of ERK1/2 and PKB in VSMC (9, 59). Since both ERK1/2 and PKB 
signaling pathways play a critical role in mediating hypertrophic and cell survival responses (1), 
it is reasonable to suggest that the ability of curcumin to inhibit the IGF-1 and ET-1-induced 
activation of these pathways may be due to its antioxidative properties. In light of these findings, 
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it may be suggested that curcumin-induced inhibition of both PKB and ERK1/2 signaling, and 
Egr-1 expression, may at least, partially contribute to the vascular protective effect of curcumin. 
In summary, this is the first report demonstrating that curcumin attenuates the signaling 
responses of ET-1 and IGF-1 in A-10 VSMC. We demonstrated that curcumin attenuated both 
IGF-1 and ET-1-stimulated increase of PKB, c-Raf, ERK1/2 and IGF-1R activation and Egr-1 
expression in A-10 VSMC. Since ERK1/2, PKB and Egr-1 play a key role in mediating VSMC 
growth and hypertrophy, it may be suggested that the ability of curcumin to attenuate these 
pathways may serve as a potential mechanism by which it counteracts the biological response of 
IGF-1 and ET-1 and exerts a vascular protective effect. 
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Figure Legends 
 
Figure 1. Curcumin attenuates ET-1 and IGF-1-induced PKB phosphorylation in A-10 
VSMC. A. Serum-starved quiescent A-10 cells were pretreated without or with the indicated 
curcumin concentrations for 30 minutes, followed by 100nM of ET-1 for 5 minutes. B. Serum-
starved quiescent A-10 cells were pretreated without or with the indicated curcumin 
concentrations for 30 minutes, followed by 6.5nM of IGF-1 for 5 minutes. Cell lysates were 
immunoblotted by phospho-specific-Ser473-PKB antibody (top panels of each section). Blots 
were also analyzed for total PKB (middle panels of each section). Bottom panels (bar diagrams) 
represent average data quantified by densitometric scanning of protein bands shown in the top 
panel. Values are the means ± SE of 6 distinct western blots from 3 independent experiments that 
were performed in duplicate, and are expressed as fold increase over basal phosphorylation, 
which is taken as 1. No results were excluded. P<0.05 considered as statistically significance 
versus ET-1 or IGF-1 alone.* indicates that P<0.05, ** indicated that P<0.005, and *** indicates 
that P<0.0005. 
 
Figure 2. Curcumin attenuates ET-1 and IGF-1-induced ERK1/2 phosphorylation in A-10 
VSMC. A. Serum-starved quiescent A-10 cells were pretreated without or with the indicated 
curcumin concentrations for 30 minutes, followed by 100nM of ET-1 for 5 minutes. B. Serum-
starved quiescent A-10 cells were pretreated without or with the indicated curcumin 
concentrations for 30 minutes, followed by 6.5nM of IGF-1 for 5 minutes. Cell lysates were 
immunoblotted by phospho-specific –Tyr204ERK1/2 antibody as shown in the top panels of each 
section. Blots were also analyzed for total ERK1/2 (middle panels of each section). Bottom 
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panels (bar diagrams) represent average data quantified by densitometric scanning of protein 
bands shown in the top panel. Values are the means ± SE of 6 distinct western blots from 3 
independent experiments that were performed in duplicate, and are expressed as fold increase 
over basal phosphorylation, which is taken as 1. No results were excluded. P<0.05 considered as 
statistically significance versus ET-1 or IGF-1 alone.* indicates that P<0.05, ** indicated that 
P<0.005, and *** indicates that P<0.0005. 
 
Figure 3. Curcumin attenuates ET-1 and IGF-1-induced c-Raf phosphorylation in A-10 
VSMC. A. Serum-starved quiescent A-10 cells were pretreated without or with the indicated 
curcumin concentrations for 30 minutes, followed by 100nM of ET-1 for 5 minutes. B. Serum-
starved quiescent A-10 cells were pretreated without or with the indicated curcumin 
concentrations for 30 minutes, followed by 6.5nM of IGF-1 for 5 minutes. Cell lysates were 
immunoblotted by phospho-Ser338-specific-c-Raf antibody as shown in the top panels of each 
section. Blots were also analyzed for total c-Raf (middle panels of each section). Bottom panels 
(bar diagrams) represent average data quantified by densitometric scanning of protein bands 
shown in the top panel. Values are the means ± SE of 6 distinct western blots from 3 independent 
experiments that were performed in duplicate, and are expressed as fold increase over basal 
phosphorylation, which is taken as 1. No results were excluded. P<0.05 considered as statistically 
significance versus ET-1 or IGF-1 alone.* indicates that P<0.05, ** indicated that P<0.005, and 
*** indicates that P<0.0005. 
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Figure 4. Curcumin attenuates ET-1 and IGF-1-induced IGF-1R tyrosine phosphorylation 
in A-10 VSMC. A. Serum-starved quiescent A-10 cells were pretreated without or with the 
indicated curcumin concentrations for 30 minutes, followed by 100nM of ET-1 for 5 minutes. B. 
Serum-starved quiescent A-10 cells were pretreated without or with the indicated curcumin 
concentrations for 30 minutes, followed by 6.5nM of IGF-1 for 5 minutes. Cell lysates were 
immunoblotted by phospho-specific IGF-1R (phospho-Tyr1158/1162/1163) antibody as shown in the 
top panels of each section. Blots were also analyzed for total IGF-1R (middle panels of each 
section). Bottom panels (bar diagrams) represent average data quantified by densitometric 
scanning of protein bands shown in the top panel. Values are the means ± SE of 6 distinct 
western blots from 3 independent experiments that were performed in duplicate, and are 
expressed as fold increase over basal phosphorylation, which is taken as 1. No results were 
excluded. P<0.05 considered as statistically significance versus ET-1 or IGF-1 alone.* indicates 
that P<0.05, ** indicated that P<0.005, and *** indicates that P<0.0005. 
 
Figure 5. Egr-1 is upregulated by ET-1 and IGF-1 in A-10 VSMC. A. Serum-starved 
quiescent A-10 cells were treated without or with 100nM ET-1 for the identified time periods. B. 
Serum-starved quiescent A-10 cells were treated without or with 6.5nM of IGF-1 for the 
identified time periods. Nuclear fractions of the cell lysates were immunoblotted by Egr-1 
antibody as shown in the top panels of each section. Blots were also analyzed for protein loading, 
using GAPDH (middle panels of each section). Bottom panels (bar diagrams) represent average 
data quantified by densitometric scanning of protein bands shown in the top panel. Values are the 
means ± SE of 6 distinct western blots from 3 independent experiments that were performed in 
duplicate, and are expressed as fold increase over basal phosphorylation, which is taken as 1. No 
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results were excluded. P<0.05 considered as statistically significance versus control.* indicates 
that P<0.05. 
 
Figure 6.  Curcumin downregulates Egr-1 in response to ET-1 and IGF-1 in A-10 VSMC. 
A. Serum-starved quiescent A-10 cells were pretreated without or with the indicated curcumin 
concentrations for 30 minutes, followed by 100nM of ET-1 for 60 minutes. B. Serum-starved 
quiescent A-10 cells were pretreated without or with the indicated curcumin concentrations for 30 
minutes, followed by 6.5nM of IGF-1 for 60 minutes. Nuclear fractions of the cell lysates were 
immunoblotted by Egr-1 antibody as shown in the top panels of each section. Blots were 
analyzed for total nuclear protein by GAPDH (middle panels of each section). Bottom panels (bar 
diagrams) represent average data quantified by densitometric scanning of protein bands shown in 
the top panel. Values are the means ± SE of 6 distinct western blots from 3 independent 
experiments that were performed in duplicate, and are expressed as fold increase over basal 
phosphorylation, which is taken as 1. No results were excluded. P<0.05 considered as statistically 
significance versus ET-1 or IGF-1 alone. *** indicates that P<0.0005. 
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The discovery of endothelin (ET), the potent vasoconstrictor, surfaced only two decades 
ago and the endothelin peptide family has now evolved into an intricate system. Endothelin-1 
(ET-1) is the most predominant isoform synthesized by the vasculature, mainly by the vascular 
endothelium and smooth muscle cells, and is accountable for the majority of the pathobiological 
effects exerted by the endothelin peptide family. In the vascular system, ET-1 mainly exerts a 
basal vascular tone regulation. A long term upregulated ET-1 system has been suggested to 
contribute to the deterioration of vascular function that leads to the development of vascular 
diseases. ET-1 exerts its action through the activation of its endothelin receptors, ETA and ETB, 
but ETA is mainly responsible in the contribution of ET-1 to the pathogenesis of vascular 
abnormalities, such as hypertension, atherosclerosis, restenosis, and other cardiovascular 
diseases. Based on recent research, ET-1 receptor antagonists exhibit inhibition of ET-1-induced 
functional and structural alterations in the vasculature. Nevertheless, ET-1 mediates its 
pleiotropic actions through the activation of several signaling pathways and further investigation 
is required to provide a better knowledge of these ET-1 signal transducing pathways for 
designing specific therapeutic agents directed against critical components of the signaling 
systems implicated in pathological contribution of ET-1-induced vascular remodeling.  
ET-1 elicits its biological effects in a paracrine-autocrine manner through the activation of 
its G-protein-coupled receptors (GPCR). This leads to the activation of multiple signaling 
pathways including mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-
kinase/protein kinase B (PI3-K/PKB) pathways that promote cellular growth, proliferation, 
hypertrophy and survival, and these are all key processes involved in vascular cell remodeling 
often encountered in ET-1 triggered pathophysiological states. Once ET-1 activates its receptor, 
the latter recruits Ras, a small G-protein that leads to the activation of MAPK, including 
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extracellular signal-regulated kinase 1/2 (ERK1/2), c-jun-NH2-terminal kinase (JNK), and 
p38mapk (276). In parallel, ET-1 also activates PI3-K (131) and several downstream targets of 
PI3-K have also been documented, the most studied being protein kinase B (PKB), also know as 
Akt (a product of akt proto-oncogene) (5). Activation of receptor and non receptor protein 
tyrosine kinases (PTK) has been proposed to be implicated in transducing ET-1-induced 
signaling events. Epidermal growth factor receptor (EGFR) (277, 278), c-Src (278, 279), and 
Ca2+ dependent PYK2 (278-280) are amongst the PTK that are activated by ET-1. We have 
recently shown a requirement of insulin-like growth factor type 1 receptor (IGF-1R) in ET-1-
induced PKB activation in VSMC (151). However, the precise molecular mechanism responsible 
for this transactivation still remains unresolved. A possible contribution to this mechanism might 
be mediated through ROS generation. Several studies have demonstrated that ROS play a key 
role in propagating growth factor and vasoactive peptide signaling. The high levels of ET-1 
observed in hypertension and atherosclerosis lead to excessive production generation of ROS and 
in a decrease in the antioxidant status (159). At physiological concentrations, ROS generated 
within the vasculature are important signaling molecules. However, an excessive synthesis of 
ROS can overcome antioxidant mechanisms and generate deleterious effects often seen in 
cardiovascular disorders (11). The involvement of ROS in ET-1-induced activation of MAPKs 
including JNK, p38mapk and ERK1/2 has been demonstrated in cardiac fibroblasts (125). 
Moreover, a role of ROS in ET-1-induced activation of the redox-sensitive ERK1/2 and PKB 
signaling pathways has been demonstrated in VSMC (5). In this context, several studies have 
investigated the possible vascular protective effect of antioxidants. A surge of interest has 
recently erupted around the use of naturally-occurring compounds with antioxidant capacity. 
Medicinal plants are rich in phytochemicals that possess several therapeutic effects, including 
antioxidative properties. Curcumin, the main constituent of the spice turmeric that is extracted 
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from the rhizomes of the Curcuma Longa L. herb, is an ancient known phytochemical that 
exhibits a vast spectrum of biological properties, amongst them, antioxidant and anti-
inflammatory properties. It has mainly been investigated for its effects against cancer. Recent 
studies though have demonstrated that curcumin also exhibits cardiovascular protective effects 
and its actions are pleiotropic and appear to involve the regulation of transcription factors, growth 
factors, cytokines, protein kinases and others (185). Curcumin has been shown to suppress ROS 
generation (174, 202, 203) and to inhibit several of the mediators involved in the ET-1 signaling 
pathway in several cellular lines. However, the therapeutic efficacy of curcumin in ET-1-induced 
signaling has yet to be reported. Therefore, these studies were undertaken to investigate the effect 
of curcumin on ET-1-induced signaling of the redox-sensitive ERK1/2, PKB pathways which are 
believed to be key players in ET-1-induced proliferative and hypertrophic responses. In an 
attempt to understand the mechanism, we studied the effect of curcumin on ET-1-stimulated IGF-
1R, PKB, c-Raf and ERK1/2 signaling in A-10 VSMC.  
Our results are the first to report an inhibitory effect of curcumin on ET-1-stimulated 
hypertrophic and proliferative signaling in VSMC. In the first part of this study, we observed a 
dose-dependent inhibitory effect of curcumin on ET-1 stimulation of IGF-1R, PKB, c-Raf and 
ERK1/2 phosphorylation in A-10 VSMC. Given that ET-1 requires IGF-1R transactivation, we 
further investigated the effect of curcumin on IGF-1-induced signaling in VSMC. A similar dose-
dependent inhibitory effect was observed on the IGF-1-induced IGF-1R, PKB, c-Raf and ERK1/2 
phosphorylation in A-10 VSMC. Moreover, we tested if transcription factor early growth 
response-1 (Egr-1), a downstream component of ERK1/2 that is a key player in multiple 
cardiovascular pathological processes (281), is a target of curcumin in response to ET-1 as well 
as IGF-1. Curcumin attenuated ET-1 and IGF-1-induced expression of Egr-1 in VSMC. 
90 
 
 
 Taken together, we demonstrate that curcumin inhibits ET-1 and IGF-1-stimulated 
increase in the phosphorylation state of IGF-1R, PKB, c-Raf and ERK1/2, as well as Egr-1 
expression in A-10 VSMC. Since ERK1/2, PKB and Egr-1 play a crucial role in mediating 
VSMC growth and hypertrophy, it may be suggested that the ability of curcumin to attenuate 
these pathways may serve as a potential mechanism by which curcumin counteracts the 
biological responses of ET-1 and thus exerts a cardiovascular protective effect. 
 
  
 
 
CHAPITRE 4 
 
CONCLUSION 
 
 
92 
 
 
The results presented here demonstrate for the first time a negative modulatory effect of 
curcumin on ET-1-stimulated signaling components: PKB, c-Raf, ERK1/2 and IGF-1R, in A-10 
VSMC. Given the fact the curcumin exhibits a significant inhibitory effect on ET-1-induced IGF-
1R phosphorylation, we expanded our studies to investigate its effect on IGF-1-induced signaling 
and highlighted an inhibitory effect of curcumin on IGF-1-induced phosphorylation of PKB, c-
Raf, ERK1/2 and IGF-1R, in A-10 VSMC. Our work also demonstrates that curcumin inhibits 
the expression of ET-1 and IGF-1-induced transcription factor Egr-1 in VSMC (Figure 4.5). 
  
 Thus, the findings in the present study have uncovered curcumin as a potent antagonist of 
ET-1 action in VSMC. Provided that curcumin exhibits such profound inhibitory effects on ET-1-
induced signaling events that have been shown to promote mitogenic and hypertrophic actions in 
the vasculature, it may be suggested that curcumin may be beneficial in attenuating vascular 
remodeling associated with several cardiovascular diseases. However, due to its vast array of 
biological properties, curcumin is able to interfere with numerous signaling pathways and it is 
suggested that a single site of action is possibly not enough to represent all the effects of this 
substance. 
 
93 
 
 
 
 
 
Figure 4.5 Schematic hypothetical model summarizing the potential interaction of 
curcumin with ET-1 signaling pathways in VSMC.  
The ability of curcumin to inhibit ET-1-induced IGF-1Rβ phosphorylation and downstream 
phosphorylation of PKB, c-Raf and ERK1/2, along with the expression of Egr-1 suggests that 
curcumin might act upstream of IGF-1R in mediating this inhibitory effect. Curcumin may also 
inhibit oxidative stress generation thereby turn off ET-1-induced signaling in VSMC.
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